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Abstract 
Tetrafluoropyridazine 1 reacts with a range of oxygen-, nitrogen-, sulfur- and carbon-centred 
nucleophiles to give, in general, products 2 arising from substitution of fluorine para to ring nitrogen. 
Subsequent reaction of the trifluoropyridazine derivatives 2 gave a range of 4,5-di- and tri-substituted 
products 3 and 6. Related reactions of tetrafluoropyridazine 1 with difunctional nucleophiles gave 
[6,6]-, [5,6]- and [6,5,6]-polycyclic ring fused pyridazine scaffolds 4 and 9. Further functionalisation of 
scaffolds 4 by nucleophlic aromatic substitution processes involving displacement of fluorine atoms at 
activated sites ortho to ring nitrogen provide an indication of the synthetic possibilities offered using 
tetrafluoropyridazine as a starting material for the preparation of polysubstituted pyridazine and novel 
polyfunctional ring fused pyridazine systems with potential applications in the drug discovery arena. 
 
Keywords: heterocyclic scaffold, perfluoroheterocycle, multi-functional pyridazine, nucleophilic 
aromatic substitution. 
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New efficient synthetic approaches to polyfunctional pyridazine derivatives and rare heterocyclic 
systems derived from tetrafluoropyridazine are described in this paper.  
While the first identification of a pyridazine ring within a natural product structure was reported 
relatively recently,1 pyridazine heterocyclic sub-units have been incorporated into a number of 
successful pharmaceutical products such as Sulfamethoxypyridazine and Nifurprazine (antibacterial 
agents) and Minaprine (antidepressant) (Fig. 1).2 Consequently, new methodology that allows the rapid 
synthesis of libraries of novel pyridazine derivatives bearing multiple functionality for incorporation in 
drug discovery campaigns continues to be an important target for medicinal chemists. 
 
 
Figure 1 Pharmaceuticals containing pyridazine sub-units 
 
In general, pyridazine systems can be constructed by either a variety of ring-forming processes or 
reactions of an appropriately functionalised pyridazine substrate.3  For example, construction of 
pyridazine rings can be achieved by formation of the inter-heteroatom bond involving the 
intramolecular oxidative coupling of two amino groups3a, reactions of 1,4-dicarbonyl compounds with 
hydrazine3b-e and Diels-Alder type [4+2] cycloaddition (Carboni-Lindsey reaction) between 1,2,4,5-
tetrazine with either an alkene or alkyne substrate.3f,g Various approaches to the preparation of 
polysubstituted pyridazines from appropriate pyridazine substrates have been reported, including 
deprotonation of the parent heterocycle and subsequent trapping with an electrophile, such as reactions 
with LiTMP3h or heteroaryl Grignard derivatives,3i palladium-catalyzed coupling of appropriate 
halogenated pyridazine derivatives3j,k such as Negishi3l or Suzuki cross coupling processes,3m,n  or 
reaction of appropriate halogenated pyridazines by SNAr processes.3o-q  Of course, all these approaches 
have their advantages and disadvantages and the choice of synthetic strategy depends on the nature of 
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the target pyridazine system, availability of appropriate substrates, regioselectivity of functionalisation, 
functional group tolerance, cost, scalability and/or applicability to parallel synthesis techniques. 
Additionally, a lack of structural diversity in pharmaceutical company compound collections is often 
suggested to hamper the development of new drug lead candidates and, consequently, new heterocyclic 
scaffolds with novel, patentable molecular architectures are of growing importance for further 
exploration of chemical space in the search for new biologically active drug-like species. 
Consequently, the synthesis of structurally novel polycyclic ring-fused pyridazine systems, for 
example, would provide access to new areas of chemical space suitable for the assessment of novel 
biological activities. New synthetic approaches to ring-fused pyridazine systems require efficient 
access to polyheterocyclic cores which also bear suitable functional groups that would allow further 
transformation to libraries of novel ring-fused heterocyclic derivatives. 
Tetrafluoropyridazine 1 could be a highly versatile scaffold for the synthesis of a range of both 
polysubstituted pyridazine systems and polyfunctional bi- and tri-cyclic fused ring systems because, in 
principle, all four fluorine atoms could be replaced by reaction with a nucleophilic species through 
sequential nucleophilic aromatic substitution processes.(Scheme 1) In this context, we demonstrated 
that pentafluoropyridine can, for example, be transformed to a range of polysubstituted pyridine 
derivatives by sequential reaction with a variety of mono- and bi-dentate nucleophilic species which 
has allowed the synthesis of various polysubstituted bi- and tri-cyclic ring fused systems such as 
pyridopyrazine4a-c and imidopyrazine4d derivatives bearing functionality for further structural 
elaboration.  Tetrafluoropyridazine 1 was first prepared some time ago5 but the chemistry of this 
system has largely been limited to reactions in which methoxide and several amines have been reported 
to provide products arising from substitution of fluorine at the 4-position5,6 whereas polysubstitution 
processes, generally involving perfluoroalkylcarbanion nucleophiles,7  have rarely been reported. 
Consequently, we chose to study reactions of tetrafluoropyridazine 1 with a range of mono- and di-
functional nucleophiles which could, potentially, lead to many novel multiply-substituted pyridazine 
and ring-fused pyridazine systems that bear wide ranging functionality following a general synthetic 
strategy outlined in Scheme 1.  
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Scheme 1. General strategy for the synthesis of highly substituted and ring fused pyridazine derivatives 
from tetrafluoropyridazine 1. 
 
In this paper, we describe the synthesis of a range of polysubstituted, bi- and tri-cyclic ring fused 
pyridazine systems from tetrafluoropyridazine 1 which allows access to some multiply-substituted 
pyridazine derivatives and various very rare heterocyclic molecular frameworks by sequential SNAr 
methodology suitable for parallel synthesis techniques. 
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2. Results and discussion 
A series of reactions of tetrafluoropyridazine 1 with model monodentate oxygen-, nitrogen-, carbon- 
and sulfur-centred nucleophiles were carried out to extend the range of systems available for further 
functionalisation and are collated in Table 1. In general, reactions of nucleophiles with 
tetrafluoropyridazine 1 occurred at 0 oC or room temperature in the presence of the strong, non-
nucleophilic organic base di-isopropylethyl amine (DIPEA) and using THF as the reaction medium. 
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Table 1. Reactions of tetrafluoropyridazine with monofunctional nucleophiles. 
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In all cases, products 2a-k, obtained in high yields, were those derived from substitution of fluorine 
located at the 4-position as we would expect from observations reported previously.5,6 This site is the 
most activated position towards nucleophilic attack as it is para to the activating ring nitrogen and has 
two ortho and one meta activating fluorine atoms, following principles for processes involving highly 
reactive heterocycles.5,8  The structures of the products 2a-k followed from 19F NMR analysis in which 
three resonances at ca. _ 80, _ 90 and _135 ppm were observed, where resonances occurring at ca. _ 90 
ppm are indicative of fluorine located at sites ortho to ring nitrogen as is the case here.9  
Whilst all nitrogen- and oxygen-centred nucleophiles gave high yields of mono-substituted products, in 
contrast, reaction of one equivalent of thiophenol and tetrafluoropyridazine 1 gave only the 4,5-
disubstituted product 2l with no monosubstituted product observed by 19F NMR analysis of the reaction 
mixture. This reflects the strong ortho activating effect of the sulfur atom which makes the 
monosubstituted product more reactive towards nucleophiles than 1 itself.10 Thus, a higher yield of 2l 
could be obtained upon reaction of 1 with two equivalents of thiophenol in similar reaction conditions. 
In contrast, ethanethiol gave only mono-substituted product 2k consistent with the decreasing electron 
withdrawing ability of the ethanethio substituent compared to the phenylthio case.  
Reaction of 1 with phenylmagnesium bromide gave a mixture of two monosubstituted products 2m and 
2n in a 5:1 ratio by 19F NMR analysis of the crude reaction mixture, arising from substitution of the 4- 
and 3-positions respectively, from which the major product 2m could be purified by repeated 
recrystallisation. In this reaction, some competing substitution occurs at the 3-position due to the 
increased reactivity of the nucleophile which allows substitution at the less activated site ortho to ring 
nitrogen. In the case of reaction of 1 with methylmagnesium bromide, decomposition occurs, likely due 
to the highly basic reaction mixture that causes deprotonation of the pyridazyllic protons present in any 
product formed leading to complex reaction mixtures as observed in similar reactions of highly 
fluorinated pyridine derivatives.11 
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Scheme 2. Reaction of 1 with phenyl magnesium bromide 
 
Trifluoropyridazine derivatives 2 are, of course, still very electrophilic in nature and, in principle, 
products arising from substitution of the remaining ring fluorine atoms or the substituent itself are 
possible upon reaction with subsequent nucleophilic species. Consequently, our next series of reactions 
was aimed at exploring the behaviour of four selected representative trifluoropyridazine derivatives 
2a,h,k,m with model nitrogen-, oxygen-, sulfur- and carbon-centred nucleophiles to determine how the 
4-substituent affects further nucleophilic substitution processes (Table 2). All reactions were performed 
using similar conditions to those described above. 
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Table 2. Reactions of trifluoropyridazines 2a,h,k,m with nucleophiles 
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Reactions of model nucleophiles with trifluoropyridazine derivatives 2a,h,k,m gave products 3a-h 
arising from substitution at the 5-position, para to ring nitrogen. 4,5-Disubstitution was confirmed by 
19F NMR analysis which showed only resonances occuring at ca. _ 85 ppm for each compound 3a-h, 
consistent with the presence of fluorine ortho- to ring nitrogen. Reactions were noticeably slower for 
the trifluorinated pyridazines 2a,k,l,m than 1 as would be expected. 
Having established that 1 reacts, in the majority of cases, regioselectively with two equivalents of 
nucleophile successively to give products 3a-h exclusively from sequential substitution of the 4- and 5-
positions, we carried out a series of experiments to prepare ring-fused systems 4 arising from 
corresponding SNAr reactions of 1 with difunctional nucleophiles. Initial nucleophilic attack on 1 at the 
4-positon, followed by subsequent intramolecular cyclisation by substitution of fluorine attached to the 
most activated 5-position would be expected to occur. Consequently, reactions of tetrafluoropyridazine 
1 with a small range of representative difunctional nitrogen nucleophiles were performed (Table 3). In 
all cases, the bi- or tri-cyclic ring fused systems 4a-g derived from reaction at the most activated 4- and 
5-positions were synthesized and isolated in good yield.  Symmetrical ring-fused products 4a,b,f were 
readily identified by the observation of only one resonance in the 19F NMR spectra and similar 
equivalencies in the 1H and 13C NMR spectra.  Non-symmetric bicyclic and tricyclic products 4c,d,e,g 
displayed two distinct 19F NMR resonances at ca. -92.6 and -94.6 ppm which are, again, both 
characteristic of fluorine located ortho to ring nitrogen.  Interestingly, these results show opposite 
regioselectivity to a cyclisation reaction previously performed between tetrafluoropyridazine and 
catechol, which cyclized between C4 and C3.12 
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Table 3. Synthesis of polycyclic systems 4 from 1 
Nucleophile Conditions Product, Yield % Nucleophile Conditions Product, Yield %
N
N
F
F
F
F
+ Dinucleophile
Conditions
Product 4
N
H
H
N
NaHCO3
MeCN
rt, 4 h
NH
NH2
1) NaHCO3,
MeCN
reflux, 3 d;
2) DIPEA, MeCN,
MW, 180 oC, 15
min
N
N
F
N
N
F
Me
Me
4a, 92%
N
N
F
HN
F
Ph
N
4b, 46%
N NH2
NaHCO3
MeCN
reflux, 16 h
N NH2
MeCN
MW, 150 oC, 10 min
N
N
N
N
F
F
4c, 82%
N
N
N
N
F
F
4d, 58%
N NH2
MeCN
MW, 150 oC, 10 min
N
N
N
N
F
F
4e, 40%
Br
Br
HS
SH
NaHCO3
MeCN
rt, 2 h N N
F
S
S
F
4f, 65%
H2N S
NaHCO3
MeCN
reflux, 16 h
N
N
F
S
F
N
4g, 62%
1
 
 
Reaction of 1 with benzamidine in acetonitrile at reflux temperature in the presence of four equivalents 
of sodium bicarbonate yielded the uncyclised amidine derivative 5. A range of bases were reacted with 
5 in an attempt to effect the desired cyclisation but n-BuLi, LDA and LiHMDS gave complex product 
mixtures. However, cyclisation could be achieved using DIPEA and 4b was obtained in good yield 
after microwave irradiation at 180 oC for 15 minutes in an overall two step process. Annelation of 1 by 
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cyclic amino-imine and 2-aminopyridine derivatives led to the corresponding tricyclic systems 4c-e 
respectively in high yields. 
 
Whilst imidazo[4,5-d]pyridazines13 and thiazolo[4,5-d]pyridazines14 are relatively common, formed by 
reaction of appropriate 4,5-diaminopyridazines with acid chloride derivatives13 and thiazole 4,5-
dicarboxaldehyde with hydrazine respectively14, many other polycyclic systems incorporating a 
pyridazine ring subunit are very rarely reported in either the academic or patent literature and 
polyfunctional systems suitable as substrates for analogue synthesis have not been described. Only a 
very few examples of related pyridazino-tetrahydropyridazine,15  dithiino-pyridazine,16 pyridazino-
thiazine and dioxino- pyridazine17 derivatives and tricyclic systems18 have been synthesised from 
reaction of appropriate chlorinated pyridazines and  dinucleophiles or by reaction of appropriate 
dinitriles with hydrazine. 
 
Sequential trisubstitution of 1 is also possible when a sufficiently activated difluoropyridazine 3f was 
further reacted with an appropriate nucleophile. Disubstituted system 3f, was reacted with morpholine 
upon microwave irradiation at 150 °C for 90 min (Scheme 3) and 19F NMR spectroscopy of the product 
mixture showed only a single product 6 which could be isolated in 71% yield by column 
chromatography and its structure was confirmed by X-ray crystallography (Figure 2). The thiophenoxy 
group is ortho- activating to some extent and the morpholino group is slightly deactivating, explaining 
the high regioselectivity of this process. 
 
Scheme 3. Synthesis of trisubstituted derivative 6 
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Figure 2.  Molecular structure of trisubstituted derivative 6 
 
Similarly, all the [5,6]- and [6,6]-ring fused scaffolds synthesised by the processes outlined in Table 3 
possess fluorine atoms attached to the pyridine ring which, in principle, are also susceptible towards 
nucleophilic displacement. Consequently, we studied reactions of representative polycyclic products 
4b-d with a small range of model nucleophiles to illustrate the potential of these novel scaffolds for the 
synthesis of polycyclic multi-functionalised derivatives (Scheme 4).  
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Scheme 4. Reactions of ring fused systems 4b-d with nucleophiles  
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N
N
N
N
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F
N
N
N
N
F
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+
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MeCN
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NaOMe
EtNH2
Et2NH
7c, Nuc = OMe, 40% 7c : 8c, 76 : 24
7d, Nuc = NHEt, 65% 7d : 8d, 79 : 21
7e, Nuc = NEt2, 70% 7e : 8e, 95 : 5
2 equiv.
7 8
+ n-BuNH2
 
 
Reaction of [6,6]-fused system 4a with nucleophiles was not successful even after prolonged heating 
with various reactive nucleophiles, reflecting the deactivating influence of the two amino substituents 
attached to the pyridazine ring. However, reaction of imidazopyridazine 4b with n-butylamine yielded 
the disubstituted system 7a, arising from replacement of both remaining ring fluorine atoms while 
reaction of tricyclic scaffold 4c with morpholine gave 7b regioselectively (Scheme 3) and the structure 
was confirmed by X-ray crystallography (Fig. 3).   
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Figure 3.  Molecular structure of 7b 
 
The regioselectivity of the reaction between 4c and morpholine can be explained by a consideration of 
the relative stabilities of the Meisenheimer intermediates formed by reaction at either the C-1 or C-4 
sites. Attack at C-1 allows delocalisation of the negative charge formed over the pyridazine and 
imidazopyridazine ring system giving a more stable intermediate whilst attack at C-4 only allows 
delocalisation over the pyridazine ring (Scheme 5). 
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Scheme 5. Regioselectivity of nucleophilic substitution for reaction of 4c 
 
 
 
Tricyclic system 4d reacted with nucleophiles under microwave irradiation in acetonitrile (Scheme 4) 
to give major products arising from substitution of fluorine at C-1. While small quantities of products 
arising from substitution of C-4 of the pyridazine ring were observed by 19F NMR analysis of the 
reaction mixture, major products 7c,d could be isolated by column chromatography or recrystallisation 
of the crude product mixture. X-ray crystallography confirmed the structure of the 1-diethylamino 
derivative 7e (Fig. 4) and NMR data obtained for 7a,b were comparable to those obtained for 7e. In 
this case, nucleophilic attack at C-1 leads to stabilisation of the Meisenheimer intermediate over the 
entire aromatic system whilst attack at C-4 only allows charge to be delocalised over the pyridazine 
ring and, consequently, reactions arising from displacement of fluorine at C-1 are preferred. 
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Figure 4. Molecular structure of 7e 
 
An alternative method for the synthesis of functionalized pyridazine ring fused polycyclic derivatives is 
to carry out annelation reactions of monofunctionalised trifluoropyridazines 2 with appropriate 
difunctional nucleophiles (Table 4).  
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Table 4. Reaction of trifluoropyridazines 2a,k with difunctional nucleophiles 
2 Conditions Product, Yield % Conditions Product, Yield %
N
N
F
F
R
F
N
N
Nuc2
Nuc1
R
F
N
N
N
FF
F
O
N
N
N
FN
N
O
N
H
H
N
DIPEA, THF
rt, 5 d
2a
9a, 84%
N
N
N
FF
F
O
N
N
N
FS
O
O
SH
OH
2a
N
N
S
FF
F N
N
S
FN
N
2k 9c, 77%
N
N
S
FF
F
N
N
S
FS
O
2k
9d, 74%
N
N
S
FF
F N
N
S
F
H
N
O
NH2
OH
2k
9e, 75%
N
N
S
FF
F
N
N
S
F
H
N
S
NH2
SH
2k 9f, 63%
N
N
S
FF
F
N
N
S
FN
N
NH2N
2k
9g, 14%
N
N
S
FF
F
N
N
S
FN
N
NH2N
2k
9h, 50%
O
OEt
O
N
N
S
FF
F
N
N
S
F
O
O
EtO
2k
9i, 28%
DIPEA, THF
rt, 16 h
9b, 68%
N
H
H
N
DIPEA, THF
rt, 16 h
SH
OH
DIPEA, THF
rt, 16 h
DIPEA, THF
100 oC, microwave,
5 min
DIPEA, THF
100 oC, microwave
30 min
DIPEA, THF
150 oC, microwave
30 min
DIPEA, THF
rt, 7 d
DIPEA, THF
180 oC, microwave
90 min
Difunctional
nucleophile
2 9
2
Conditions
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Indeed, reaction of N,N’-dimethylethylene diamine with 2a gave the desired fused product 9a in good 
yield after stirring in THF at room temperature and, similarly, reaction with 2-mercaptophenol gave 
tricyclic product 9b. 4-(Ethylthio)-3,5,6-trifluoropyridazine 2k was also used for the synthesis of ring 
fused systems and reaction with N,N’-dimethylethylene diamine rapidly gave fused bicyclic product 9c 
in good yield. 2-Mercaptophenol gave the fused bicyclic product 9d as the only product as observed by 
19F NMR analysis of the crude reaction mixture and crystals that were suitable for analysis by X-ray 
crystallography allowed the confirmation of the structure (Fig. 5). It appears that the initial attack is 
performed by the sulfur atom giving initial substitution para to ring nitrogen, further activating the 
intermediate to nucleophilic attack by the oxygen atom at the adjacent site. 
 
Figure 5. Molecular structures of 9d, 9e and 9h. 
 
Reaction of 2k with 2-aminophenol using microwave irradiation at 100 °C for five minutes gave the 
tricyclic product 9e, confirmed by X-ray crystallography (Fig. 5), which demonstrated that the product 
was formed via initial attack by nitrogen followed by cyclisation through oxygen. Similarly, 2-
aminobenzenethiol, 2-aminopyridine, 2-amino-3-picoline and ethyl acetoacetate gave the desired 
polycyclic products 9f-i respectively after reaction with 4-(ethylthio)-3,5,6-trifluoropyridazine 2k 
under microwave irradiation. 
 
3. Conclusions 
Tetrafluoropyridazine 1 may be used as a very effective scaffold for the synthesis of a range of 4,5-
disubstituted pyridazine systems bearing oxygen, nitrogen, sulfur and carbon functionality. Further 
substitution of the difluorinated systems gave mixtures of trisubstituted pyridazine systems, processes 
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which were particularly regioselective in the presence of an ortho-activating sulfur substituent. 
Consequently, we have further extended our general strategy for using perfluorinated heteroaromatic 
scaffolds for analogue synthesis to pyridazine systems. 
Novel bi- and tri-cyclic heterocyclic systems have been synthesised by reaction of tetrafluoropyridazine 
with bifunctional nitrogen centred nucleophiles providing access to tetrahydropyrazino-pyridazine, 
imidazopyridazine and tetraazafluorene scaffolds. The presence of fluorine atoms attached to sites 
activated towards nucleophilic attack allows functionalisation of these scaffolds and representative 
examples of nucleophilic aromatic substitution processes have been established. The developing use of 
highly fluorinated heteroaromatic derivatives as starting materials for heterocyclic synthesis has been 
further expanded to ring fused pyridazine systems. 
 
The general strategy outlined in Scheme 1 has allowed the synthesis of a wide range of 
polyfunctionalised and ring-fused pyridazine derivatives from tetrafluoropyridazine and the synthetic 
methodology is summarised in Scheme 6, demonstrating the diverse molecular structures that can be 
accessed very readily after a few simple operations. 
 
Scheme 6. Synthesis of pyridazine based systems from tetrafluoropyridazine 
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4. Experimental 
 
General 
Reactions were performed under an atmosphere of argon gas using dry solvents.  Microwave reactions 
were performed on a Biotage Initiator 60 EXP.  Reactions were monitored by 19F NMR or TLC on 
silica gel TLC plates.  Column chromatography was carried out on silica gel (Merck no. 109385, 
particle size 0.040 – 0.063nm) or using a Biotage Horizon or Isco Companion flash chromatography 
system.  Mass directed HPLC was performed on a Supelco LCABZ++ column using MicroMass 
MassLynx v4.0 software. Melting points were recorded using a Gallenkamp melting point apparatus at 
atmospheric pressure and are uncorrected. NMR spectra were recorded in deuteriochloroform, unless 
otherwise stated, using trichlorofluoromethane as an internal reference on a Varian Mercury 400 or 
Bruker Avance 400 operating at 400MHz (1H NMR), 376MHz (19F NMR) and 100MHz (13C NMR), or 
a Varian Inova 500 operating at 500MHz (1H NMR), 470MHz (19F NMR) and 125MHz (13C NMR), or 
a Varian VNMRS-700 operating at 700MHz (1H NMR), 658MHz (19F NMR) and 175MHz (13C 
NMR).  Chemical shifts are given in ppm and coupling constants are recorded in Hertz. Mass spectra 
were recorded on a Thermoquest Trace GC-MS spectrometer (in electron ionisation mode) or a 
Micromass LCT LC-MS spectrometer (in electrospray ES+ mode).  Exact mass measurements were 
performed on a Thermo-Finnigan LTQ-FT spectrometer. Gas chromatography was carried out on a 
Thermo TRACE GC.  Analytical HPLC was performed on an Analytical Varian LC (5ml/min). 
Elemental analyses were obtained using an Exeter Analytical E-440 Elemental Analyser. 
 
X-ray crystallography 
 
The X-ray single crystal data have been collected on a Bruker SMART CCD 1K (compounds 7b and 
9e), a Bruker SMART CCD 6000 (compounds 7e, 9d and 9h) and a Rigaku R-AXIS SPIDER IP 
(compound 6) diffractometers (graphite monochromators, λMoKα, λ =0.71073Å) equipped with a 
Cryostream (Oxford Cryosystems) open-flow nitrogen cryostats at the temperatures 120(2) K. All 
structures were solved by direct method and refined by full-matrix least squares on F2 for all data using 
Olex219 and SHELXTL20 software. All non-disordered non-hydrogen atoms were refined 
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anisotropically, hydrogen atoms were refined isotropically, the hydrogen atoms in the twinned structure 
9e were placed in the calculated positions and refined in riding mode. Crystallographic data for the 
structures have been deposited with the Cambridge Crystallographic Data Centre as supplementary 
publications CCDC-1486844-1486849. 
 
Reactions of Tetrafluoropyridazine 1 with nucleophiles 
General procedure 
A mixture of tetrafluoropyridazine 1, DIPEA, amine and THF (10 mL) was stirred for the required time 
under an atmosphere of nitrogen. The mixture was evaporated to dryness in vacuo, partitioned between 
ethyl acetate (20 mL) and water (20 mL), the phases were separated and the aqueous phase was 
extracted further by ethyl acetate (3 x 20 mL). The combined organic phases were dried (MgSO4) and 
evaporated in vacuo. Purification by column chromatography or HPLC on silica gel using cyclohexane 
and ethyl acetate as eluent gave the pure product.  
4-(3,5,6-Trifluoro-pyridazin-4-yl)morpholine 2a 
Tetrafluoropyridazine 1 (781 mg, 5.14 mmol), DIPEA (1.35 mL, 7.73 mmol), morpholine (0.45 mL, 
5.17 mmol) and THF (10 mL) after stirring at 0 °C for 2 h gave 4-(3,5,6-trifluoro-4-
pyridazinyl)morpholine 2a (908 mg, 81%) as white crystals; mp 34.5 – 36.1 °C (Found: [MH]+, 
220.06923. C8H8F3N3O requires: [MH]+, 220.06922); νmax(film)/cm-1 2970, 2902, 2860 and 1595; δH 
3.54 (4 H, br s, CH2N), 3.80 - 3.86 (4 H, m, CH2O); δC 50.1 (t, 4JCF 4.4, CH2N), 66.7 (s, CH2O), 129.3 
(ddd, 2JCF 24.8, 2JCF 24.8, 3JCF 3.2, C-4), 139.7 (ddd, 1JCF 270.8, 2JCF 28.8, 3JCF 9.6, C-5), 156.8 (ddm, 
1JCF 240.5, 3JCF 12.0, C-6), 158.0 (dd, 1JCF 240.5, 2JCF 3.2, C-3); δF -143.8 – -143.4 (1F, m, F-5) -98.6 
(1 F, dd, 3JFF 31.0, 4JFF 24.1, F-3) -80.8 (1 F, dd, 3JFF 28.7, 5JFF 28.7, F-6); m/z (ES+) 220 ([MH]+, 
100%). 
N,N-Diethyl-3,5,6-trifluoro-4-pyridazinamine 2b 
Tetrafluoropyridazine 1 (774 mg, 5.09 mmol), DIPEA (1.33 mL, 7.64 mmol), diethylamine (0.53 mL, 
5.09 mmol) and THF (10 mL) after stirring at 0 °C for 19 h gave N,N-diethyl-3,5,6-trifluoro-4-
pyridazinamine 2b (852 mg, 82%) as a yellow oil; (Found: [MH]+, 206.08973. C8H8F3N3O requires: 
206.08996); νmax(film)/cm-1 2983, 2940 and 1587; δH 1.28 (6 H, t, 3JHH 7.1, CH3), 3.47 (4 H, qt, 3JHH 
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7.1, 5JHF 1.5, CH2); δC 13.9 (s, CH3), 46.8 (t, 4JCF 5.2, CH2), 129.2 (dt, 2JCF 25.6, 3JCF 4.8, C-4), 137.9 
(ddd, 1JCF 266.8, 2JCF 28.8, 3JCF 11.2, C-5), 157.0 (dd, 1JCF 238.1, 3JCF 2.4, C-3), 157.1 (dd, 1JCF 238.9, 
2JCF 4.0, C-6); δF -146.8 (1 F, dd, 3JFF 27.5, 4JFF 25.2, F-5), -100.7 (1 F, dd, 4JFF 28.7, 5JFF 24.1, F-3), -
81.4 (1 F, dd, 3JFF 28.7, 5JFF 28.7 F-6); m/z (ES+) 206 ([MH]+, 100%). 
N-Allyl-3,5,6-trifluoro-N-methylpyridazin-4-amine 2c 
Tetrafluoropyridazine 1 (785 mg, 5.16 mmol), DIPEA (1.35 mL, 7.73 mmol), N-methylallylamine 
(0.50 mL, 5.16 mmol) and THF (10 mL) after stirring at 0 °C for 3.5 h gave N-allyl-3,5,6-trifluoro-N-
methylpyridazin-4-amine 2c (861 mg, 82%) as a pale yellow oil; (Found: [M]+, 204.07433. C8H8F3N3O 
requires:  [M]+, 204.07431); νmax(film)/cm-1 2908, 1644 and 1593; δH 3.14 (3 H, t, 5JHF 3.2, CH3), 3.97 
(2 H, d, 3JHH 5.9, CH2), 5.29 (1 H, dd, 3JHH 16.9, 2JHH 1.2, HCH), 5.32 (1 H, dd, 3JHH 10.3, 2JHH 1.2, 
HCH), 5.82 - 5.94 (1 H, m, CH); δC 39.6 (t, 4JCF 5.6, CH3), 57.3 (t, 4JCF 4.8, CH2), 119.1 (s, =CH2), 
130.1 (dt, 2JCF 25. 6, 3JCF 4.8, C-4), 132.2 (s, CH), 138.4 (ddd, 1JCF 267.6, 2JCF 28.0, 3JCF 9.6, C-5), 
157.0 (dd, 1JCF 239.7, 3JCF 12.8, C-3), 157.2 (dd, 1JCF 238.9, 2JCF 4.8, C-6); δF -145.6 (1 F, dd, 3JFF 
27.5, 4JFF 27.5, F-5) -100.0 (1 F, dd, 4JFF 28.7, 5JFF 25.2, F-3) -80.9 (1 F, dd, 3JFF 28.7, 5JFF 28.7, F-6); 
m/z (ES+) 204 ([M]+, 100%). 
N-[(4-bromophenyl)methyl]-3,5,6-trifluoro-N-methyl-4-pyridazinamine 2d 
Tetrafluoropyridazine 1 (786 mg, 5.17 mmol), DIPEA (1.3 mL, 7.46 mmol), 1-(4-bromophenyl)-N-
methylmethanamine (1.05 mL, 5.26 mmol) and THF (10 mL) after stirring at rt for 3 h gave N-[(4-
bromophenyl)methyl]-3,5,6-trifluoro-N-methyl-4-pyridazinamine 2d (1.122 g, 65%) as white crystals, 
mp 77.1 – 78.5 °C (Found: C, 43.4; H, 2.70; N, 12.4. C12H9BrF3N3 requires: C, 43.4; H, 2.7; N, 
12.6%); νmax(film)/cm-1 2940, 1601, 1573 and 1560; δH 3.09 (3 H, dd, 5JHF 3.8, 5JHF 2.7, CH3) 4.53 (2 
H, s, CH2) 7.15 (2 H, d, 3JHH 8.5, H2C-C-CH) 7.49 (2 H, d, 3JHH 8.5 Hz, Br-C-CH); δC 40.0 (t, 4JCF 5.2, 
CH3), 57.6 (t, 4JCF 4.8, CH2), 121.9 (br s, C-Br), 129.0 (s, H2C-C-CH), 130.2 (ddd, 2JCF 24.8, 2JCF 4.8, 
3JCF 3.2, C-4), 132.0 (s, Br-C-CH), 134.9 (br s, H2C-C), 139.0 (ddd, 1JCF 270.8, 2JCF 29.6, 3JCF 10.4, C-
5), 156.9 (dd, 1JCF 240.5, 3JCF 11.9, C-6), 157.4 (dd, 1JCF 239.7, 2JCF 3.9, C-3); δF -144.3 (1 F, t, 3JFF 
26.4, F-5) -99.4 (1 F, dd, 4JFF 27.5, 5JFF 25.2, F-3) -80.6 (1 F, dd, 3JFF 29.8, 5JFF 29.8, F-6); m/z (ES+) 
334.1 ([MH]+, 100%). 
Methyl N-methyl-N-(3,5,6-trifluoro-4-pyridazinyl)glycinate 2e 
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Tetrafluoropyridazine 1 (801 mg, 5.27 mmol), DIPEA (2.29 mL, 13.17 mmol), sarcosine methyl ester 
hydrochloride (735 mg, 5.27 mmol) and THF (10 mL), after stirring at rt for 3 d gave methyl N-methyl-
N-(3,5,6-trifluoro-4-pyridazinyl)glycinate 2e (616 mg, 50%) as a pale yellow oil; (Found: C, 40.5; H, 
3.3; N, 17.7. C8H8F3N3O requires: C, 40.9; H, 3.4; N, 17.9%); νmax(film)/cm-1 2958, 1747 and 1597; δH 
3.27 (3 H, dd, 5JHF 3.4, 5JHF 2.7, NCH3), 3.81 (3 H, s, OCH3), 4.14 (2 H, s, CH2); δC 42.1 (t, 4JCF 5.6, 
NCH3), 52.5 (s, OCH3), 55.3 (dd, 4JCF 6.4, 4JCF 4.8, CH2), 129.62 (ddd, 2JCF 25.6, 2JCF 4.8, 3JCF 3.2, C-
4), 138.77 (ddd, 1JCF 269.2, 2JCF 28.8, 3JCF 9.6, C-5), 156.9 (d, 1JCF 240.0, C-3), 157.0 (dd, 1JCF 238.9, 
2JCF 3. 9, C-6), 169.3 (s, C=O); δF -144.6 (1 F, t, 3JFF 26.4, F-5), -99.3 (1 F, dd, 4JFF 28.7, 5JFF 24.09, F-
3), -81.0 (1 F, t, 3JFF 28.7, F-6); m/z (ES+) 236.1 ([MH]+, 100%).  
3,5,6-Trifluoro-N-phenylpyridazin-4-amine 2f 
Tetrafluoropyridazine 1 (776 mg, 5.10 mmol), DIPEA (1.35 mL, 7.73 mmol) and aniline (0.46 mL, 
5.10 mmol) in THF (10 mL), after stirring at 0 °C for 4 h and purification by column chromatography 
on silica gel using ethyl acetate:hexane as eluent, gave 3,5,6-trifluoro-N-phenylpyridazin-4-amine 2f 
(895 mg, 78%) as a white solid, mp 123.2 – 124.0 °C (Found: C, 53.6; H, 2.8; N, 18.7. C10H6F3N3 
requires: C, 53.3; H, 2.7; N, 18.7%); δH 6.47 (1 H, br. s, NH), 7.15 – 7.40 (5 H, m, ArH); δC 122.7 (d, 
5JCF 2.6, C-2’), 124.2 – 124.3 (m, C-4), 126.5 (s, C-4’), 129.4 (s, C-3’), 136.5 (ddd, 1JCF 272.3, 2JCF 
29.9, 3JCF 6.9, C-5), 137.1 (s, C-1’), 156.8 (dd, 1JCF 238.2, 2JCF 3.3, C-6), 156.9 (d, 1JCF 237.7, C-3); δF 
-141.5 (1 F, dd, 4JFF 25.4, 3JFF 24.5, F-5), -98.9 (1 F, dd, 5JFF 29.5, 3JFF 24.5, F-6), -89.0 (1 F, dd, 5JFF 
29.5, 3JFF 25.4, F-3); m/z (ES+) 224.9 ([MH]+, 100%). 
3,4,6-Trifluoro-5-(2-propen-1-yloxy)pyridazine 2g 
Tetrafluoropyridazine (780 mg, 5.13 mmol), DIPEA (1.3 mL, 7.46 mmol), allyl alcohol (0.36 mL, 5.26 
mmol) and THF (10 mL) after stirring at reflux for 24 h gave 3,4,6-trifluoro-5-(2-propen-1-
yloxy)pyridazine 2g (716 mg, 73%) as a colourless oil; (Found: [MH]+, 191.04277. C7H5F3N2O 
requires:  [MH]+, 191.04267); νmax/cm-1 2898, 1648 and 1611; δH 5.03 (2 H, dd, 3JHH 6.0, 5JHF 0.9, O-
CH2), 5.44 (1 H, dd, 3JHH 10.5, 2JHH 1.0, CHH), 5.51 (1 H, dd, 3JHH 16.9, 2JHH 0.97, CHH), 5.96 - 6.09 
(1H, m, CH); δC 74.6 (dd, 4JCF 5.6, 3JCF 1.6, O-CH2), 121.4 (s, CH2), 130.5 (s, CH), 136.0 - 136.4 (m, 
C-5), 140.1 (ddd, 1JCF 277.2, 2JCF 28.8, 3JCF 7.9, C-4), 156.7 (ddd, 1JCF 242.0, 3JCF 11.2, 4JCF 1.6, C-6), 
158.7 (d, 1JCF 242.9, C-3); δF -146.6 (1 F, dd, 3JFF 25.2, 5JFF 25.2, F-4), -95.8 (1 F, dd, 4JFF 29.8, 5JFF 
26.4, F-6), -87.6 (1 F, dd, 3JFF 27.5, 5JFF 27.5, F-3); m/z (ES+) 191.0 ([MH]+, 100%). 
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3,4,6-Trifluoro-5-[(1-methylethyl)oxy]pyridazine 2h 
Tetrafluoropyridazine 1 (780 mg, 5.13 mmol), DIPEA (1.3 mL, 7.46 mmol), isopropanol (0.41 mL, 
5.26 mmol) and THF (10 mL) after stirring at reflux for 24 h gave 3,4,6-trifluoro-5-[(1-
methylethyl)oxy]pyridazine 2h (713 mg, 72%) as a colourless oil; (Found: [MH]+, 193.05830. 
C7H7F3N2O requires:  [MH]+, 193.05832); νmax/cm-1 2990, 2941 and 1608; δH 1.47 (6 H, dd, 3JHH 6.1, 
6JHF 0.8, CH3), 5.02 - 5.14 (1 H, m, CH); δC 22.5 (s, CH3), 78.8 (d, 4JCF 4.0, CH), 136.0 - 136.2 (m, C-
5), 140.0 (ddd, 1JCF 275.8, 2JCF 28.6, 3JCF 7.8, C-4), 156.7 (ddd, 1JCF 239.7, 3JCF 11.2, 4JCF 1.6, C-6), 
159.1 (ddd, 1JCF 246.1, 2JCF 8.8, 4JCF 2.4, C-3); δF  -147.0 (1 F, dd, 3JFF 25.2, 4JFF 25.2, F-4) -96.1 (1 F, 
dd, 4JFF 28.7, 5JFF 26.4, F-6) -87.9 (1 F, dd, 3JFF 28.7, 5JFF 28.7, F-3); m/z (ES+) 193.2 ([MH]+, 100%). 
4-(Cyclohexyloxy)-3,5,6-trifluoropyridazine 2i 
Tetrafluoropyridazine 1 (777 mg, 5.11 mmol), DIPEA (1.3 mL, 7.46 mmol), cyclohexanol (0.55 mL, 
5.29 mmol) and THF (10 mL) after stirring at rt for 6 d gave 4-(cyclohexyloxy)-3,5,6-
trifluoropyridazine 2i (752 mg, 63%) as a colourless oil; (Found: C, 51.7; H, 4.5; N, 11.8. 
C10H11F3N2O requires: C, 51.7; H, 4.8, N, 12.1%); νmax(film)/cm-1 2940, 2863 and 1607; δH 1.02 - 2.37 
(10 H, m, CH2), 4.80 (1 H, br s, CH); δC 23.0 (s, C-3’), 24.9 (s, C-4’), 32.0 (s, C-2’), 83.3 (d, 4JCF 3.4, 
C-1’), 135.8 - 136.0 (m, C-4), 140.2 (ddd, 1JCF 275.6, 2JCF 27.9, 4JCF 7.9, C-5), 156.7 (ddd, 1JCF 242.0, 
3JCF 11.1, 4JCF 1.6, C-3), 159.3 (dd, 1JCF 244.4, 2JCF 2.4, C-6); δF -146.3 (1 F, dd, 3JFF 26.4, 4JFF 26.4, F-
5), -95.8 (1 F, dd, 4JFF 29.8, 5JFF 26.4, F-3), -87.5 (1 F, dd, 3JFF 28.7, 5JFF 28.7, F-6); m/z (ES+) 233.2 
([MH]+, 100%). 
3,4,6-Trifluoro-5-[(4-methylphenyl)oxy]pyridazine 2j 
Tetrafluoropyridazine 1 (768 mg, 5.05 mmol), DIPEA (1.3 mL, 7.46 mmol), p-cresol (0.53 mL, 5.07 
mmol) and THF (10 mL) after stirring at rt for 26 h gave 3,4,6-trifluoro-5-[(4-
methylphenyl)oxy]pyridazine 2j (740 mg, 60%) as a colourless oil (Found: C, 54.9; H, 2.9; N, 11.4. 
C11H7F3N2O requires: C, 55.0; H, 2.9; N, 11.7%); νmax(film)/cm-1 2928, 1614, 1606 and 1571; δH 2.38 
(3 H, s, CH3), 6.97 (2 H, d, 3JHH 8.7, O-C-CH), 7.21 (2 H, dd, 3JHH 8.7, 4JHH 0.7, H3C-C-CH); δC 20.7 
(s, CH3), 116.9 (s, O-C-CH), 130.5 (s, H3C-C-CH), 134.5 - 134.7 (m, C-5), 135.7 (s, H3C-C), 141.8 
(ddd, 1JCF 282.8, 2JCF 27.9, 3JCF 7.1, C-4), 153.0 (s, O-C), 156.7 (ddd, 1JCF 243.6, 2JCF 9.9, 4JCF 2.3, C-
3), 159.2 (d, 1JCF 246.8, C-6); δF -140.4 (1 F, dd, 3JFF 24.1, 4JFF 24.1, F-4), -94.0 (1 F, dd, 4JFF 31.0, 5JFF 
24.1, F-6), -85.5 (1 F, dd, 3JFF 29.8, 5JFF 24.1, F-3); m/z (ES+) 241.2 ([MH]+, 100%). 
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4-(Ethylthio)-3,5,6-trifluoropyridazine 2k 
Tetrafluoropyridazine 1 (780 mg, 5.13 mmol), DIPEA (1.35 mL, 7.73 mmol), ethanethiol (0.30 mL, 4.1 
mmol) and THF (10 mL) after stirring at 0 °C for 1 h gave 4-(ethylthio)-3,5,6-trifluoropyridazine 2k 
(514 mg, 65%) as a colourless oil; δH 3.27 (2 H, qt, 3JHH 7.4, 5JHF 1.1, CH2), 1.40 (3 H, t, 3JHH 7.4, 
CH3); δF -74.6 (1F, dd, 3JFF 30.2, 4JFF 21.0, F-5), -99.4 (1 F, dd, 3JFF 30.2, 5JFF 26.4, F-6), -124.8 (1 F, 
dd, 5JFF 26.4, 4JFF 21.0, F-3); m/z (AP+) 195.0210 (C6H6N2F3S requires 195.0204). 
3,6-Difluoro-4,5-bis(phenylthio)pyridazine 2l 
Tetrafluoropyridazine 1 (780 mg, 5.13 mmol), DIPEA (2.6 mL, 14.8 mmol), thiophenol (1 mL, 9.7 
mmol) and THF (10 mL) after stirring at rt overnight gave 3,6-difluoro-4,5-bis(phenylthio)pyridazine 
2l (1314 mg, 77%) as yellow crystals; mp 99.1 – 100.3 °C (Found: C, 57.7; H, 3.0; N, 8.3. 
C16H10F2N2S2 requires: C, 57.8; H, 3.0; N, 8.4%); νmax/cm-1 1578, 1500 and 1377; δH 7.34 - 7.47 (10 H, 
m, CH); δC 129.3 (s, C-4’), 129.6 (s, C-3’), 130.2 (s, C-1’), 132.2 (s, C-2’), 133.6 (dd, 2JCF 17.5, 3JCF 
15.9, C-4), 162.6 (dd, 1JCF 249.2, 4JCF 6.3, C-3); δF -75.8 (br s); m/z (ES+) 333.2 ([MH]+, 100%). 
3,4,6-Trifluoro-5-phenylpyridazine 2m 
Tetrafluoropyridazine (780 mg, 5.13 mmol), phenylmagnesium bromide (1M solution in THF, 5.13 
mL, 5.13 mmol) and THF (10 mL) under nitrogen at -78 °C and warmed to rt for 16 h and 
recrystallisation from cyclohexane gave 3,4,6-trifluoro-5-phenylpyridazine 2m (501 mg, 47%) as white 
crystals; m.p. 82.7 – 83.4 °C (Found: C, 57.1; H, 2.4; N, 13.2. C10H5F3N2 requires: C, 57.1; H, 2.4; N, 
13.3%); νmax/cm-1 1580, 1558, 1458 and 1445; δH 7.56 - 7.62 (5 H, m, CH); δC 121.2 (ddd, 2JCF 31.9, 
2JCF 8.7, 3JCF 4.0, C-5), 123.6 (br s, C-4’), 129.0 (s, C-2’), 129.7 (br s, C-3’), 131.1 (s, C-1’), 147.8 
(ddd, 1JCF 281.2, 2JCF 27.1, 3JCF 7.9, C-4), 156.5 (ddd, 1JCF 243.6, 3JCF 12.7, 4JCF 2.4, C-6), 162.30 (d, 
1JCF 245.2, C-3); δF -129.3 (1 F, dd, 3JFF 26.4, 4JFF 21.8, F-4), -97.6 (1 F, dd, 5JFF 31.0, 3JFF 26.4, F-3), -
79.6 (1 F, dd, 5JFF 31.0, 4JFF 21.8, F-6); m/z (ES+) 211.2 ([MH]+, 100%). 
 
Reactions of Trifluoropyridazine derivatives 
General procedure 
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A mixture consisting of DIPEA, nucleophile, trifluorophenylpyridazine and THF was heated and 
stirred as approprite. The mixture was concentrated in vacuo, partitioned between EtOAc (20 mL) and 
water (20 mL) and the aqueous phase was further extracted with EtOAc (2 x 20 mL). The combined 
organic phases were concentrated in vacuo and dried (MgSO4). Column chromatography on silica gel 
gave the difunctional difluoropyridazine product. 
 
4-(3,6-Difluoro-5-phenyl-4-pyridazinyl)morpholine 3a 
DIPEA (0.18 mL, 1.03 mmol), morpholine (0.06 mL, 0.68 mmol), 3,4,6-trifluoro-5-phenylpyridazine 
2m (143 mg, 0.680 mmol) and THF (10 mL) after stirring at rt for 4 d and column chromatography on 
silica gel using a 5-25% THF in cyclohexane gradient as eluent gave 4-(3,6-difluoro-5-phenyl-4-
pyridazinyl)morpholine 3a (61 mg, 32 %) as white crystals; mp 180.6 – 182.0 °C (Found: C, 60.5; H, 
4.7; N, 15.0. C10H5F3N2 requires: C, 60.6; H, 4.7; N, 15.1%); νmax/cm-1 2977, 2857 and 1543; δH 3.04 
(4 H, td, 3JHH 4.7, 5JHF 1.6, NCH2), 3.61 (4 H, dd, 3JHH 4.8, 3JHH 4.6, OCH2), 7.31 - 7.38 (2 H, m, CH), 
7.42 - 7.57 (3 H, m, CH); δC 50.5 (d, 4JCF 4.8, NCH2), 66.5 (s, OCH2), 120.2 (dd, 2JCF 31.2, 3JCF 6.4, C-
5), 128.9 (s, C-2’), 129.4 (s, C-3’), 129.5 (br s, C-4’), 129.6 (t, 3JCF 2.4, C-1’), 139.2 (dd, 2JCF 22.4, 3JCF 
6.4, C-4), 159.3 (d, 1JCF 240.5, C-3), 163.3 (d, 1JCF 239.7, C-6); δF -86.9 (1 F, d, 5JFF 31.6, F-3), -84.0 
(1 F, d, 5JFF 31.6, F-6); m/z (ES+) 278.2 ([MH]+, 100%). 
 
4-{3,6-Difluoro-5-[(1-methylethyl)oxy]-4-pyridazinyl}morpholine 3b  
Method A: DIPEA (0.20 mL, 1.15 mmol), morpholine (0.07 mL, 0.80 mmol), 3,4,6-trifluoro-5-[(1-
methylethyl)oxy]pyridazine 2l (153 mg, 0.80 mmol) and THF (10 mL) after stirring at rt for 4 d and 
column chromatography on silica gel using a 5-25% THF in cyclohexane gradient as eluent gave 4-
{3,6-difluoro-5-[(1-methylethyl)oxy]-4-pyridazinyl}morpholine 3b (163 mg, 79 %) as white crystals; 
mp 73.9 – 75.4 °C (Found: [MH]+, 260.12041. C11H15F2N3O2 requires: [MH]+, 260.12051); νmax/cm-1 
2980, 2861, 1566; δH 1.33 (6 H, d, 3JHH 6.2, CH3), 3.39 (4 H, dd, 3JHH 4.4, 5JHF 3.3, NCH2), 3.76 (4 H, 
t, 3JHH 4.4, OCH2), 4.63 - 4.76 (1 H, m, 3JHH 6.2, 5JHF 1.4, CH); δC 22.3 (s, CH3), 50.4 (d, 4JCF 4.8, 
NCH2), 66.9 (s, OCH2), 77.1 (d, 4JCF 5.6, CH), 133.2 (dd, 2JCF 23.2, 3JCF 8.0, C-4), 137.0 (dd, 2JCF 24.8, 
3JCF 8.8, C-5), 159.5 (d, 1JCF 239.7, C-3), 160.4 (d, 1JCF 240.5, C-6); δF -93.2 (1 F, d, 5JFF 29.8, F-6), -
86.2 (1 F, d, 5JFF 29.8, F-3); m/z (ES+) 260.3 ([MH]+, 100%). 
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Method B: Lithium isopropoxide (2 M in THF, 0.45 mL, 0.90 mmol), 4-(3,5,6-trifluoro-4-
pyridazinyl)morpholine 2a (195 mg, 0.89 mmol) and THF (10 mL) at -78 °C, stirring for 16 h at rt  
overnight and column chromatography on silica gel using a 2-13% EtOAc in toluene gradient as eluent 
gave 4-{3,6-difluoro-5-[(1-methylethyl)oxy]-4-pyridazinyl}morpholine 3b (94 mg, 41%) as white 
crystals; physical and spectroscopic data as above. 
 
4-(5-(Ethylthio)-3,6-difluoropyridazin-4-yl)morpholine 3c 
DIPEA (0.27 mL, 1.5 mmol), morpholine (0.09 mL, 1.03 mmol), 4-(ethylthio)-3,5,6-
trifluoropyridazine 2k (200 mg, 1.03 mmol) and THF (10 mL) after stirring at rt for 16 h and column 
chromatography on silica gel using hexane as eluent gave 4-(5-(ethylthio)-3,6-difluoropyridazin-4-
yl)morpholine 3c (197 mg, 73%) as a yellow oil; (Found: C, 45.6; H, 5.1; N, 16.2. C10H13F2N3OS 
requires: C, 45.9; H, 5.0; N, 16.1%); νmax/cm-1 2965, 2853, 1638 and 1546; δH 1.29 (3 H, td, 3JHH 7.4, 
6JHF 0.5, CH3), 3.09 (2 H, qd, 3JHH 7.4, 5JHF 1.6, SCH2), 3.41 (4 H, td, 3JHH 4.7, 5JHF 2.3, NCH2), 3.84 (4 
H, t, 3JHH 4.7, OCH2); δC 14.9 (d, 5JCF 0.9, CH3), 28.5 (d, 4JCF 8.9, SCH2), 51.0 (d, 4JCF 4.6, NCH2), 
67.1 (d, 5JCF 1.5, OCH2), 121.3 (dd, 2JCF 32.6, 3JCF 6.8, C-4), 140.9 (dd, 2JCF 23.4, 3JCF 7.1, C-5), 159.5 
(dd, 1JCF 243.2, 4JCF 1.5, C-6), 164.7 (d, 1JCF 237.9, C-3); δF -88.4 (1 F, d, 5JFF 31.2, F-3), -78.5 (1 F, d, 
5JFF 31.2, F-6); m/z (ES+) 260.9 ([M]+, 100%). 
 
 
3,6-Difluoro-4-phenyl-5-(phenylthio)pyridazine 3d 
DIPEA (0.19 mL, 1.1 mmol), thiophenol (0.07 mL, 0.68 mmol), 3,4,6-trifluoro-5-phenylpyridazine 2m 
(150 mg, 0.714 mmol) and THF (10 mL) after stirring at 0 °C for 1 hour and column chromatography 
on silica gel using 1-7% THF in cyclohexane gradient as eluent gave 3,6-difluoro-4-phenyl-5-
(phenylthio)pyridazine 3d (188 mg, 88%) as off-white crystals; mp 78.9 – 80.0 °C (Found: C, 64.0; H, 
3.4; N, 9.3. C16H10F2N2S2 requires: C, 64.0; H, 3.4; N, 9.3%); νmax/cm-1 1523, 1443 and 1386; δH 7.20 - 
7.31 (5 H, m, ArH), 7.33 - 7.40 (2 H, m, ArH), 7.44 - 7.55 (3 H, m, ArH); δC 128.6 (s, C-2’), 128.8 (d, 
3JCF 2.4, C-1’), 128.9 (s, C-4’’), 129.3 (s, C-3’’), 129.4 (s, C-3’), 130.1 (s, C-4’), 130.3 (d, 4JCF 2.4, C-
1’’), 132.0 (s, C-2’’), 132.4 (dd, 2JCF 29.6, 3JCF 4.0, C-4), 134.5 (dd, 2JCF 31.2, 3JCF 3.2, C-5), 162.1 (d, 
1JCF 245.3, C-6), 163.3 (d, 1JCF 244.5, C-3); δF -83.3 (1 F, d, 5JFF 31.0, F-3), -75.3 (1 F, d, 5JFF 31.0, F-
6); m/z (ES+) 301.2 ([MH]+, 100%). 
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3,6-Difluoro-4-[(1-methylethyl)oxy]-5-(phenylthio)pyridazine 3e 
DIPEA (0.22 mL, 1.3 mmol), thiophenol (0.08 mL, 0.75 mmol), 3,4,6-trifluoro-5-[(1-
methylethyl)oxy]pyridazine 2l (160 mg, 0.833 mmol) and THF (10 mL) after stirring at 0 °C for 1 h 
and column chromatography on silica gel using 1-7% THF in cyclohexane gradient as eluent gave 3,6-
difluoro-4-[(1-methylethyl)oxy]-5-(phenylthio)pyridazine 3e (77 mg, 33%) as pale yellow crystals; mp 
45.1 – 46.9 °C (Found: [MH]+, 283.07113. C13H12F2N2OS requires: [MH]+, 283.07112); νmax/cm-1 
2985, 1581 and 1544; δH 1.26 (6 H, dd, 3JHH 6.1, 6JHF 0.9, CH3), 4.97 - 5.08 (1 H, m, CH), 7.29 - 7.43 
(5 H, m, ArH); δC 22.4 (s, CH3), 78.4 (d, 5JCF 8.0, CH), 121.1 (dd, 2JCF 32.0, 3JCF 7.2, C-5), 128.6 (s, C-
4’), 129.3 (s, C-3’), 130.6 (s, C-1’), 131.8 (s, C-2’), 147.0 (dd, 2JCF 24.0, 3JCF 6.4, C-4), 157.8 (d, 1JCF 
241.3, C-6), 163.8 (d, 1JCF 240.5, C-3); δF -92.1 (1 F, d, 5JFF 31.6, F-3), -76.5 (1 F, d, 5JFF 31.6, F-6); 
m/z (ES+) 283.2 ([MH]+, 76%). 
 
 
4-[3,6-Difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 3f 
DIPEA (0.15 mL, 0.88 mmol), thiophenol (0.06 mL, 0.58 mmol), 4-(3,5,6-trifluoro-4-
pyridazinyl)morpholine 2a (129 mg, 0.589 mmol) and THF (10 mL) after stirring at 0 °C for 1 h and  
column chromatography on silica gel using 5-25% EtOAc in cyclohexane gradient as eluent gave 4-
[3,6-difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 3f (146 mg, 80%) as pale yellow crystals; mp 
109.7 – 111.2 °C (Found: C, 54.1; H, 4.2; N, 13.6. C14H13F2N3OS requires: C, 54.4; H, 4.2; N, 13.6%); 
νmax/cm-1 2982, 1581 and 1542; δH 3.40 (4 H, td, 3JHH 4.7, 5JHF 2.1, NCH2), 3.70 (4 H, dd, 3JHH 4.7, 
3JHH 4.5, OCH2), 7.21 - 7.25 (2 H, m, ArH), 7.30 - 7.37 (3 H, m, ArH); δC 50.4 (d, 4JCF 4.8, NCH2), 
66.8 (s, OCH2), 116.3 (dd, 2JCF 32.0, 3JCF 5.6, C-4), 128.0 (s), 129.0 (s), 129.5 (s), 131.9 (s), 141.4 (dd, 
2JCF 23.2, 3JCF 4.8, C-5), 159.0 (d, 1JCF 243.7, C-6), 164.9 (d, 1JCF 239.7, C-3); δF -86.2 (1 F, d, 5JFF 
31.0, F-3), -76.0 (1 F, d, 5JFF 31.0, F-6); m/z (ES+) 310.2 ([MH]+, 100%). 
 
4-(Ethylthio)-3,6-difluoro-5-isopropoxypyridazine 3g 
Lithium isopropoxide (2 M in THF, 0.58 mL, 1.16 mmol), 4-(ethylthio)-3,5,6-trifluoropyridazine 2k 
(227 mg, 1.17 mmol) and THF (10 mL) at -78 °C, was allowed to stir for 16 h at rt and after column 
chromatography on silica gel using hexane:EtOAc (9:1) as eluent gave 4-(ethylthio)-3,6-difluoro-5-
isopropoxypyridazine 3g (213 mg, 78 %) as a colourless oil; (Found: C, 46.4; H, 5.3; N, 11.8. 
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C9H12F2N2OS requires: C, 46.1; H, 5.2; N, 12.0% ); δH 1.31 (3 H, t, 3JHH 7.4, CH2CH3), 1.42 (6 H, d, 
3JHH 5.9, CHCH3), 3.16 (2 H, qd, 3JHH 7.4, 5JHF 1.3, CH2), 4.99 (1 H, hept d, 3JHH 5.9, 5JHF 1.3, CH); δC 
15.1 (s, CH2CH3), 22.8 (s, CHCH3), 27.3 (d, 4JCF 7.1, CH2), 78.7 (d, 4JCF 7.2, CH), 123.3 (dd, 2JCF 32.8, 
3JCF 6.6, C-4), 146.8 (dd, 2JCF 24.4, 3JCF 7.8, C-5), 158.2 (dd, 1JCF 242.4, 4JCF 2.1, C-3), 164.0 (d, 1JCF 
238.4, C-6); δF -93.8 (1 F, d, 5JFF 31.1, F-6), -78.7 (1 F, d, 5JFF 31.1, F-3); m/z (ES+) 235.1 ([MH]+, 
100%). 
 
3,6-Difluoro-4-isopropoxy-5-phenylpyridazine 3h 
Lithium isopropoxide (2 M in THF, 0.40 mL, 0.80 mmol), 3,4,6-trifluoro-5-phenylpyridazine 2m (169 
mg, 0.804 mmol) and THF (10 mL) at -78 °C, was allowed to stir for 16 h at rt and after column 
chromatography on silica gel using 5-13% EtOAc in cyclohexane gradient as eluent gave 3,6-difluoro-
4-isopropoxy-5-phenylpyridazine 3h (138 mg, 69%) as a colourless oil; δH 1.22 (6 H, dd, 3JHH 6.1, 6JHF 
0.6, CH3), 4.65 - 4.77 (1 H, m, CH), 7.49 - 7.52 (5 H, m, ArH); δF -92.3 (1 F, d, 5JFF 32.1, F-3), -83.0 (1 
F, d, 5JFF 32.1, F-6); m/z (ES+) 251.2 ([MH]+, 92%). 
 
 
Reactions of tetrafluoropyridazine with difunctional nucleophiles 
 
5,8-Difluoro-1,2,3,4-tetrahydro-1,4-dimethylpyrazino-[2,3-d]pyridazine 4a 
A mixture of tetrafluoropyridazine 1 (0.60 g, 3.96 mmol), N,N’-dimethylethylene diamine (0.47 ml, 4.4 
mmol), sodium hydrogen carbonate (1.33 g, 15.8 mmol) and acetonitrile (100 mL) was stirred at rt for 
4 h.  Water (50 mL) was added and the mixture was extracted with ethyl acetate (3 × 30 mL).  The 
combined organic extracts were dried (MgSO4), filtered and evaporated. Column chromatography on 
silica gel using ethyl acetate : hexane (1:1) as eluent gave 5,8-difluoro-1,2,3,4-tetrahydro-1,4-
dimethylpyrazino-[2,3-d]pyridazine 4a (0.62 g, 92 %) as white crystals; mp 169 – 171 oC (Found: C, 
47.9; H, 5.0; N, 27.8. C8H10N4F2 requires: C, 48.0; H, 5.0; N, 28.0%); νmax / cm-1 1092, 1159, 1251, 
1343, 1410, 1557, 2900 (br); δH 3.05 (6H, br s, CH3), 3.20 (4H, br s, CH2); δC  42.2 (s, CH3), 48.4 (s, 
CH2), 125.8 (dd, 2JCF 16.7, 3JCF 16.7, C-4a), 156.2 (dd, 1JCF 235.2, 4JCF 3.8, C-5); δF  -92.1 (s); m/z 
(EI+) 200 ([M]+, 100%), 185 (42), 156 (20), 42 (76). 
 
N-(3,5,6-Trifluoropyridazin-4-yl)benzamidine 5 
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A mixture of tetrafluoropyridazine 1 (0.60 g, 3.96 mmol), benzamidine hydrochloride (0.68 g, 
4.35mmol), sodium hydrogen carbonate (1.32 g, 15.8 mmol) and acetonitrile (100 mL) was heated at 
reflux for 16 h.  After this period, the solvent was evaporated and the residue dissolved in ethyl acetate 
(50 mL).  Water (25 mL) was added and the aqueous layer extracted with ethyl acetate (2 × 25 mL).  
The combined organic extracts were dried (MgSO4), filtered, evaporated, recrystallised from ethyl 
acetate and hexane (1:1) to give N-(3,5,6-trifluoropyridazin-4-yl)benzamidine  5 (0.76 g, 75%) as a 
yellow solid; mp 139 – 141 oC (Found: [MH]+, 253.06956. C11H7F3N4 requires: [MH]+, 253.06956); δH 
(DMSO-d6) 7.6  – 7.9 (5H, m, Ar-H), 8.08 (1H, br s, NH); δC (DMSO-d6) 127.6 (s, C-2’), 128.4 (s, C-
3’), 131.4 (dd, 2JCF 31.4, 3JCF 10.4, C-4), 131.6 (s, C-4’), 133.4 (s, C-1’), 141.9 (ddd, 1JCF 269.1, 2JCF 
26.8, 3JCF 9.3, C-5), 156.2 (dd, 1JCF 235.8, 2JCF 11.4, C-6), 159.5 (s, C=N), 160.6 (d, 1JCF 239.4, C-3); 
δF (DMSO-d6) -86.9 (1F, t, 3JFF 27.6, F-3), -101.0 (1F, t, 3JFF 27.6, F-6), -140.0 (1F, t, 3JFF 27.6, F-5); 
m/z (EI+) 252 ([M]+, 32), 104 (61), 77 (100). 
 
4,7-Difluoro-2-phenyl-1H-imidazo[4,5-d]pyridazine 4b 
A mixture of N-(3,5,6-trifluoropyridazin-4-yl)benzamidine 5 (0.25 g, 0.99 mmol), 
diisopropylethylamine (0.17 mL, 1.0 mmol) and  acetonitrile (2.5 mL) was subjected to microwave 
irradiation at 150 oC for 60 min.  Water (25 mL) was added and the mixture was extracted with 
dichloromethane (3 × 25 mL).  The combined organic extracts were dried (MgSO4), filtered, 
evaporated and recrystallised from toluene to give 4,7-difluoro-2-phenyl-1H-imidazo[4,5-d]pyridazine 
4b (0.19 g, 62%) as a yellow solid; mp 220 oC (decomp.) (Found: [MH]+, 233.06326. C11H6F2N4 
requires: [MH]+, 233.06333); δH (DMSO-d6) 7.5 – 7.7 (3H, m, ArH), 8.1 – 8.3 (2H, m, ArH); δC 
(DMSO-d6) 127.5 (s, C-2’), 129.0 (s, C-3’), 129.7 (s, C-4’), 131.0 (s, C-1’), 154.8 (d, 2JFF 19.8, C-3a), 
155.9 (dd, 1JCF 243.4, 4JCF 8.7, C-4), 159.0 (s, C=N); δF (DMSO-d6) -89.3 (s); m/z (ES+) 233 ([MH]+, 
100%). 
 
1,4-Difluoro-5,6,7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene 4c 
A mixture of tetrafluoropyridazine 1 (0.50 g, 3.28 mmol), 2-iminopiperidine (0.98 g, 7.22 mmol), 
sodium hydrogen carbonate (1.10 g, 13.1 mmol) and acetonitrile (100 mL) was stirred at rt for 3 d. The 
solvent was evaporated and the crude mixture partitioned between ethyl acetate (25 mL) and water (50 
mL).  The aqueous layer was separated and acidified with dil. HCl (10%), then extracted with ethyl 
acetate (2 × 25 mL) and dichloromethane (3 × 25 mL).  The combined organic extracts were dried 
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(MgSO4), filtered and evaporated. Column chromatography on silica gel with ethyl acetate : 
dichloromethane (2:1) as eluent gave 1,4-difluoro-5,6,7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene 4c 
(0.57 g, 82%) as a yellow solid; mp 152 – 154 oC (Found: C, 51.0; H, 3.9; N, 26.7. C9H8N4F2 requires: 
C, 51.4; H, 3.8; N, 26.4%); δH 2.0 – 2.1 (2H, m, CH2), 2.1 – 2.2 (2H, m, CH2), 3.1 – 3.2 (2H, m, H-8), 
4.3 – 4.4 (2H, m, H-5); δC 19.7 (s, CH2), 22.2 (s, CH2), 25.6 (s, CH2), 45.9 (s, C-5), 125.1 (dd, 2JCF 
28.0, 3JCF 11.7, C-4a), 133.5 (dd, 2JCF 32.9, 3JCF 6.5, C-9a), 153.4 (d, 1JCF 237.6, C-4), 157.6 (d, 1JCF 
244.4, C-1), 157.7 (s, C-8a); δF -92.6 (1F, d, 5JFF 32.9), -94.6 (1F, d, 5JFF 32.9); m/z (EI+) 210 ([M]+, 
100%), 209 ([M-H]+, 36), 182 (32), 181 (14). 
 
1,4-Difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene 4d 
A mixture of tetrafluoropyridazine 1 (0.50 g, 3.28 mmol), 2-amino-3-picoline (0.83 mL, 8.22 mmol) 
and acetonitrile (1 mL) was subjected to microwave irradiation at 150oC for 60 min.  Water (25 mL) 
was added and the mixture was extracted with dichloromethane (3 × 25 mL).  The combined organic 
extracts were dried (MgSO4), filtered and evaporated and recrystallised. Column chromatography on 
silica gel with dichloromethane as eluent gave 1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene 4d 
(0.42 g, 58%) as a white solid; mp 213 – 215 oC (Found: [MH]+, 221.06339. C10H6N4F2 requires: 
[MH]+, 221.06333); νmax / cm-1 1580, 1433, 1379, 1309, 1281, 1256, 1228, 1165, 1102, 1024, 976; δH 
2.79 (3H, s, CH3), 7.21 (1H, t, 3JHH 7.2, H-6), 7.59 (1H, d, 3JHH 7.2, H-7), 8.63 (1H, d, 3JHH 7.2, H-5); 
δC 17.7 (s, CH3), 115.6 (s, C-6), 119.0 (dd, 2JCF 26.9, 3JCF 11.6, C-4a), 125.6 (d, 4JCF 4.9, C-5), 130.1 (s, 
C-8), 131.8 (s, C-7), 135.3 (dd, 2JCF 35.1, 3JCF 6.2, C-9a), 151.9 (s, C-8a), 154.0 (dd, 1JCF 238.6, 4JCF 
2.4, C-4), 158.2 (dd, 1JCF 246.9, 4JCF 3.5, C-1); δF -89.7 (1F, d, 5JFF 34.6, F-1), -91.6 (1F, d, 5JFF 34.6, 
F-4); m/z (EI+) 220 ([M]+, 100%). 
 
6-Bromo-1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene 4e 
A mixture of tetrafluoropyridazine 1 (0.50 g, 3.28 mmol), 2-amino-5-bromo-3-methylpyridine (1.68 g, 
8.20 mmol) and acetonitrile (10 mL) was subjected to microwave irradiation at 150 oC for 60 min.  
Water (25 mL) was added and the mixture was extracted with dichloromethane (3 × 25 mL).  The 
combined organic extracts were dried (MgSO4), filtered and evaporated and recrystallised. Column 
chromatography on silica gel with dichloromethane as eluent gave 6-bromo-1,4-difluoro-8-methyl-
2,3,4b,9-tetraaza-fluorene  4e (0.36 g, 40%) as a cream solid; mp 215 – 217 oC (Found: C, 40.2; H, 
2.0; N, 18.5. C10H6N4F2 requires: C, 40.2; H, 1.7; N, 18.7%); νmax / cm-1 996, 1028, 1106, 1159, 1247, 
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1279, 1310, 1326, 1413, 1433, 1470, 1558; δH 2.78 (3H, s, CH3), 7.66 (1H, s, H-7), 8.73 (1H, s, H-5); 
δC 17.5 (s, CH3), 110.2 (s, C-6), 118.6 (dd, 2JCF 26.9, 3JCF 11.9, C-4a), 125.4 (d, 4JCF 4.6, C5), 131.0 (s, 
C-8), 135.1 (dd, 2JCF 36.4, 3JCF 6.9, C-9a), 135.3 (s, C-7), 150.1 (s, C-8a), 153.6 (dd, 1JCF 236.8, 4JCF 
2.8, C-4), 158.2 (dd, 1JCF 246.8, 4JCF 3.4, C-1); δF -89.0 (1F, d, 5JFF 34.8, F-4), -90.9 (1F, d, 5JFF 34.8, 
F-1); m/z (EI+) 300 ([M]+, 100%), 298 ([M]+, 93), 219 (62), 154 (26), 102 (40), 90 (30), 77 (44), 63 
(57), 51 (60), 39 (34). 
 
5,8-difluoro-2,3-dihydro-[1,4]dithiino[2,3-d]pyridazine 4f 
Tetrafluoropyridazine 1 (0.25 g, 1.64 mmol) was dissolved in dry acetonitrile (20 mL) and 1,2-
ethanedithiol (0.15 mL, 1.81 mmol) and sodium hydrogen carbonate (0.28 g, 3.29 mmol) were added.  
The mixture was allowed to stir at rt for 2 h before the solvent was evaporated, and the crude reaction 
mixture partitioned between dichloromethane (20 mL) and water (20 mL).  The aqueous layer was 
separated before extraction with further portions of dichloromethane (3 × 20 mL).  The combined 
organic extracts were then dried (MgSO4), filtered and evaporated o provide a crude yellow material 
which after recrystallisation from acetonitrile gave 5,8-difluoro-2,3-dihydro-[1,4]dithiino[2,3-
d]pyridazine 4f (0.29g, 85%) as a white solid; mp 123 – 125oC; δH 3.41 (4H, s, CH2); δC 25.5 (s, C-2), 
126.0 (dd, 2JCF 20.0, C-4a), 160.0 (dd, 1JCF 242.2, 4JCF 5.1, C-5); δF -84.8 (s); m/z (EI+) 206 (88%, M+), 
191 (100), 178 (19, [M-N2]+), 132 (19), 87 (29). 
 
4,7-difluoro-2-methylthiazolo[4,5-d]pyridazine 4g 
Tetrafluoropyridazine 1 (1.00 g, 6.58 mmol) was mixed with thioacetamide (0.54 g, 7.23 mmol) and 
sodium hydrogen carbonate (2.21 g, 26 mmol) in acetonitrile (50 mL) under argon.  The mixture was 
stirred at reflux for 16 h, after which the solvent was evaporated, and the crude mixture dissolved in 
ethyl acetate (25 mL) and water (25 mL).  The aqueous layer was separated and acidified with HCl 
(10%), then extracted with ethyl acetate (2 × 25 mL) and dichloromethane (3 × 25 mL).  The combined 
organic extracts were dried (MgSO4), filtered and evaporated to yield a crude brown product. Column 
chromatography on silica gel using  ethyl acetate as eluent and recrystallisation from acetonitrile gave 
4,7-difluoro-2-methylthiazolo[4,5-d]pyridazine  4g (0.76g, 62%) as a yellow solid; mp > 250 oC; δH 
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(DMSO-d6) 3.00 (3H, s, CH3); δC 20.7 (s, CH3), 129.4 (dd, 2JCF 38.8, 3JCF 16.8, C-3a), 161.0 (dd, 1JCF 
243.0, 4JCF 6.0, C-4), 178.9 (s, C-2); δF (658MHz, DMSO-d6) -81.4 (s); m/z (EI+) 187 (M+, 30%), 117 
(24), 87 (100), 70 (92), 31 (97). 
 
Reaction of 4-[3,6-difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 3f 
 
4,4'-(6-Fluoro-4-(phenylthio)pyridazine-3,5-diyl)dimorpholine 6 
A mixture consisting of morpholine (56 mg, 0.626 mmol), DIPEA (84 mg, 1.20 mmol), 4-[3,6-
difluoro-5-(phenylthio)-4-pyridazinyl]morpholine 3f (204 mg, 0.626 mmol) and THF (4 mL) was 
irradiated at 150 °C (microwave) for 80 min. The mixture was concentrated, partitioned between 
EtOAc (10 mL) and water (10 mL), and extracted with two further portions of EtOAc (2 x10 mL). The 
combined organic phases were dried (MgSO4) and evaporated and the residue after column 
chromatography on silica gel using a hexane:ethyl acetate gradient as eluent gave 4,4'-(6-fluoro-4-
(phenylthio)pyridazine-3,5-diyl)dimorpholine 6 (168 mg, 71%) as white crystals; mp 159.3 – 160.0 °C 
(Found: [MH]+, 377.1436. C18H21F2N4O2S requires: [MH]+, 377.1448); δH 3.15 - 3.19 (4H, m, CH2NC-
5), 3.31 (4H, t, 3JHH 4.7, CH2), 3.61 (4H, t, 3JHH 4.7, CH2), 3.64 (4H, t, 3JHH 4.7, CH2), 7.06 - 7.09 (2H, 
m, ArH), 7.22 - 7.29 (3H, m, ArH); δC 50.5 (s, CH2), 50.6 (d, 4JCF 4.2, CH2), 66.6 (s, CH2), 66.9 (s, 
CH2), 121.4 (d, 3JCF 6.9, C-4), 127.6 (s, C-4’), 128.4 (s, C-3’), 129.2 (s, C-2’), 133.8 (s, C-1’), 140.2 (d, 
2JCF 23.4, C-5), 158.7 (d, 1JCF 241.2, C-6), 163.9 (s, C-3); δF -92.57 (s); m/z (ES+) 377.1 ([MH]+, 
100%). Crystal data for 6: C18H21N4O2FS, M = 376.45, monoclinic, space group P 21, a = 6.58813(2), 
b = 13.5706(4), c = 10.4143(4) Å, β = 107.70(2)°, U = 886.07(5) Å3, F(000) = 396, Z = 2, Dc = 1.416 
mg m-3, µ = 0.214 mm-1. 16499 reflections were collected yielding 5013 unique data (Rmerg = 0.0534). 
Final wR2(F2) = 0.0885 for all data (319 refined parameters), conventional R1(F) = 0.0364 for 4793 
reflections with I≥2σ(I), GOF = 1.053, Flack parameter -0.01(5). CCDC-1486844. 
 
 
Reactions of scaffolds 4b-d with nucleophiles 
 
N4,N7-dibutyl-2-phenyl-1H-imidazo[4,5-d]pyridazine-4,7-diamine 7a 
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4,7-Difluoro-2-phenyl-1H-imidazo[4,5-d]pyridazine 4b (0.10g, 0.43mmol) was dissolved in 
acetonitrile (1mL) in a 0.5 - 2 mL microwave vial, n-butylamine (0.085 ml, 0.86 mmol) was added and 
the vial sealed.  The mixture was heated by microwave irradiation at 150oC for 20 min before 
dichloromethane (10 mL) and water (10 mL) were added and the layers separated.  The aqueous layer 
was then washed with further portions of dichloromethane (3 × 10 mL) and the organic extracts 
combined, dried (MgSO4), filtered and evaporated to yield a crude yellow material.  Column 
chromatography on silica gel using ethyl acetate as eluent gave N4,N7-dibutyl-2-phenyl-1H-
imidazo[4,5-d]pyridazine-4,7-diamine  7a (51 mg, 35 %) as yellow crystals; mp 173 – 175oC; δH 0.8 – 
0.9 (6H, m, CH3), 1.33 (4H, sextet, 3JHH 7.4, CH2CH3), 1.61 (4H, pent, 3JHH 7.4, CH2CH2CH3), 3.36 
(4H, t, 3JHH 7.4, NCH2), 7.3 – 7.5 (3H, m, ArH), 8.1 – 8.3 (1H, m, ArH); δC 13.9 (s, CH3), 20.3 (s, 
CH2CH2), 31.3 (s, CH2CH2CH3), 41.7 (s, NHCH2), 116.2 (s), 118.9 (s), 127.3 (s), 129.0 (s), 129.7 (s), 
132.7 (s), 147.1 (s); m/z (ES+) 339 ([MH]+, 100%). 
 
4-Fluoro-1-morpholin-4-yl-5,6,7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene 7b 
A mixture of 1,4-difluoro-5,6,7,8-tetrahydro-2,3,4b,9-tetraaza-fluorene 4c (0.10 g, 0.48 mmol), 
morpholine (0.083 mL, 0.95 mmol) and acetonitrile (1 mL) was heated at 150 oC (microwave) for 20 
min. Water (25 mL) was added and the mixture was extracted with dichloromethane (3 × 25 mL).  The 
combined organic extracts were dried (MgSO4), filtered and evaporated. Column chromatography on 
silica gel with ethyl acetate and hexane (2:1) as eluent gave 4-fluoro-1-morpholin-4-yl-5,6,7,8-
tetrahydro-2,3,4b,9-tetraaza-fluorene 7b (95 mg, 72%) as a yellow solid; mp 179 – 181 oC (Found: 
[MH]+, 278.14106. C13H16N5FO requires: [MH]+ 278.14117); δH 2.00 - 2.10 (2H, m, CH2), 2.12 - 2.18 
(2H, m, CH2), 3.09 (2H, t, 3JHH 6.4, CH2), 3.87 (4H, t, 3JHH 4.8, OCH2), 4.03 (4H, t, 3JHH 4.8, NCH2), 
4.33 (2H, t, 3JHH 6.0, NCH2); δC 20.2 (s, CH2), 22.6 (s, CH2), 25.5 (s, CH2), 45.3 (d, 4JCF 2.7, C-5), 47.3 
(s, C-2’), 67.2 (s, C-3’), 121.5 (d, 2JCF 27.6, C-4a), 136.1 (d, 3JCF 5.8, C-9a), 151.5 (d, 1JCF 231.6, C-4), 
152.6 (d, 4JCF 2.1, C-8a), 153.9 (d, 4JCF 2.1, C-1); δF -101.9 (s); m/z (ES+) 278 ([MH]+, 100%). Crystal 
data for 7b: C13H16N5FO, M = 277.31, orthorhombic, space group P bcn, a = 16.7598(9), b = 
7.3062(4), c = 20.4845(11) Å, U = 2508.3(2) Å3, F(000) = 1168, Z = 8, Dc = 1.469 mg m-3, µ = 0.109 
mm
-1
. 19847 reflections were collected yielding 3035 unique data (Rmerg = 0.0807). Final wR2(F2) = 
0.1179 for all data (245 refined parameters), conventional R1(F) = 0.0472 for 2114 reflections with 
I≥2σ(I), GOF = 1.025. CCDC-1486846. 
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4-Fluoro-1-methoxy-8-methyl-2,3,4b,9-tetraaza-fluorene 7c 
A mixture of 1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene 4d (0.50 g, 2.27 mmol), sodium 
methoxide (0.31 g, 5.68 mmol) and methanol (3 mL) was heated at 150 oC (microwave) for 20 min. 
Water (25 mL) was added and the mixture was extracted with dichloromethane (3 × 25 mL).  The 
combined organic extracts were dried (MgSO4), filtered and evaporated. Column chromatography on 
silica gel using hexane : ethyl acetate (2:1) as eluent gave 4-fluoro-1-methoxy-8-methyl-2,3,4b,9-
tetraaza-fluorene 7c (0.21 g, 40%) as a white solid; mp 229 – 231 oC (Found: C, 56.6; H, 3.9; N, 23.9. 
C11H9FN4O requires: C, 56.9; H, 3.9; N, 24.1%); νmax / cm-1 964, 980, 1030, 1102, 1132, 1168, 1236, 
1286, 1320, 1372, 1424, 1466, 1579; δH 2.76 (3H, s, CH3), 4.38 (3H, s, OCH3), 7.08 (1H, t, 3JHH 6.8, 
H-6), 7.48 (1H, dt, 3JHH 6.8, 4JHH 1.0, H-7), 8.80 (1H, d, 3JHH 6.8, H-5); δC 17.6 (s, CH3), 55.6 (s, 
OCH3), 114.3 (s, C-6), 120.5 (d, 3JCF 11.4, C-9a), 126.0 (s, C-5), 129.1 (s, C-8), 130.4 (s, C-7), 133.1 
(d, 2JCF 36.4, C-4a), 150.7 (s, C-8a), 154.9 (d, 4JCF 2.0, C-1), 156.8 (d, 1JCF 247.6, C-4); δF -94.5 (s); 
m/z (EI+) 232 ([M]+, 58%), 231 (39), 217 (8), 183 (100). 
 
Ethyl-(4-fluoro-8-methyl-2,3,4b,9-tetraaza-fluoren-1-yl)-amine 7d 
A mixture of 1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene 4d (0.50 g, 2.27 mmol) and 
ethylamine(2.83 mL, 2.0 M in THF, 5.68 mmol) was heated at 150 oC (microwave) for 20 min. Water 
(25 mL) was added and the mixture was extracted with dichloromethane (3 × 25 mL).  The combined 
organic extracts were dried (MgSO4), filtered, evaporated and recrystallised from toluene to give ethyl-
(4-fluoro-8-methyl-2,3,4b,9-tetraaza-fluoren-1-yl)-amine 7d (0.36g, 65%) as a yellow solid; mp 127 – 
129 oC (Found: [MH]+, 246.11492. C12H12FN5 requires: [MH]+, 246.11495); νmax / cm-1 1340, 1401, 
1435, 1480, 1583, 1616, 3351 (br); δH 1.40 (3H, t, 3JHH 6.6, CH2CH3), 2.71 (3H, s, CH3), 3.77 (2H, 
quin, 3JHH 6.6, NCH2), 5.53 (1H, br s, NH), 7.03 (1H, t, 3JHH 6.7, H-6), 7.40 (1H, dt, 3JHH 6.7, 4JHH 0.9, 
H-7), 8.51 (1H, d, 3JHH 6.7, H-5); δC 14.9 (s, CH2CH3), 17.5 (s, CH3), 36.5 (s, NHCH2), 114.2 (s, C-6), 
114.5 (d, 2JCF 29.5, C-4a), 125.5 (d, JCF 4.2, C-9a), 128.9 (s, C-5), 129.5 (s, C-7), 136.3 (s, C-8), 149.6 
(s, C-8a), 150.2 (d, 1JCF 230.6, C-4), 153.1 (d, 4JCF 2.0, C-1); δF -99.4 (s); m/z (EI+) 245 ([M]+, 17%), 
230 (29), 183 (67), 92 (58). 
 
Diethyl-(4-fluoro-8-methyl-2,3,4b,9-tetraaza-fluoren-1-yl)-amine 7e 
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A mixture of 1,4-difluoro-8-methyl-2,3,4b,9-tetraaza-fluorene 4d (0.30 g, 1.36 mmol), diethylamine 
(0.35 mL, 3.41 mmol) and acetonitrile (3 mL) was heated at 150 oC (microwave) for 20 min. Water (25 
mL) was added and the mixture was extracted with dichloromethane (3 × 25 mL).  The combined 
organic extracts were dried (MgSO4), filtered, evaporated and recrystallised from hexane / 
dichloromethane (4:1) to give diethyl-(4-fluoro-8-methyl-2,3,4b,9-tetraaza-fluoren-1-yl)-amine 7e 
(0.26 g, 70%) as yellow crystals; mp 111 – 113 oC (Found: C, 61.7; H, 5.9; N, 25.4. C14H16N5F 
requires C, 61.5; H, 5.9; N, 25.6%); νmax / cm-1 1217, 1237, 1295, 1352, 1429, 1485, 1575, 1638, 2973; 
δH 1.31 (6H, t, 3JHH 7.1, CH2CH3), 2.66 (3H, s, CH3), 4.09 (4H, q, 3JHH 7.1, NCH2), 6.95 (1H, t, 3JHH 
7.0, H-6), 7.31 (1H, d, 3JHH 7.0, H-7), 8.46 (1H, d, 3JHH 7.0, H-5); δC 13.8 (s, CH2CH3), 17.3 (s, CH3), 
44.0 (s, NCH2), 113.9 (s, C-6), 114.4 (d, 2JCF 28.0, C-4a), 125.1 (s, C-8), 128.7 (s, C-5), 129.2 (s, C-7), 
136.6 (d, 3JCF 4.6, C-8a), 148.3 (s, C-9a), 150.5 (d, 1JCF 228.4, C-4), 153.3 (d, 4JCF 1.9, C-1); δF -102.7 
(s); m/z (EI+) 273 ([M]+, 24%), 244 (100), 230 (74), 201 (12), 183 (56), 92 (36). Crystal data for 7e: 
C14H16FN5, M = 273.32, monoclinic, space group C2/c, a = 15.9765(4), b = 12.4896(3), c = 14.4663(3) 
Å, β = 114.06(1)°, U = 2635.8(1) Å3, F(000) = 1152, Z = 8, Dc = 1.378 mg m-3, µ = 0.097 mm-1. 19731 
reflections were collected yielding 3504 unique data (Rmerg = 0.0284). Final wR2(F2) = 0.1117 for all 
data (245 refined parameters), conventional R1(F) = 0.0394 for 2913 reflections with I≥2σ(I), GOF = 
1.052. CCDC-1486848. 
 
3-Fluoro-5,8-dimethyl-4-morpholin-4-yl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 9a 
DIPEA (0.25 mL, 1.5 mmol) and N,N'-dimethyl-ethane-1,2-diamine (0.05 mL, 0.5 mmol) were added 
to a stirred solution of 4-(3,5,6-trifluoro-pyridazin-4-yl)-morpholine 2a (100 mg, 0.46 mmol) in THF (4 
mL), and the mixture was stirred at rt for 5 d. The mixture was concentrated, partitioned between DCM 
(10 mL) and water (10 mL), the phases were separated and the aqueous phase further extracted with 
DCM (2 x 10 mL). The organic phases were combined, dried and concentrated. Purification by column 
chromatography on silica gel using toluene:THF (1:2) as eluent gave 3-fluoro-5,8-dimethyl-4-
morpholin-4-yl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 9a (103 mg, 84%) as white crystals; mp 
144.2 – 147.3 °C (Found: [MH]+, 268.1574. C12H18FN5O requires [MH]+, 268.1574); δH 3.08 (4H, td, 
3JHH 4.7, 5JHF 1.8, NCH2), 3.14 (3H, s, CH3), 3.30 – 3.33 (2H, m, CH2N), 3.31 (3H, s, CH3), 3.38 – 3.40 
(2H, m, CH2), 3.76 (4H, t, 3JHH 4.7, CH2O); δC 38.3 (s, CN-8), 41.4 (s, CN-5), 46.5 (s, C-7), 50.4 (d, 
4JCF 4.3, CNC-4), 51.0 (s, C-6), 67.0 (d, 5JCF 0.5, CO), 119.5 (d, 2JCF 29.1, C-4), 134.9 (d, 3JCF 8.9, C-
4a), 151.8 (s, C-8a), 161.2 (d, 1JCF 236.6, C-3); δF -94.5 (s); m/z (AP+) 267 ([M]+, 100%). 
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3-Fluoro-4-morpholin-4-yl-9-oxa-10-thia-1,2-diaza-anthracene 9b 
DIPEA (1.2 mL, 6.9 mmol) and 2-mercaptophenol (0.23 mL, 2.3 mmol) were added to a stirred 
solution of 4-(3,5,6-trifluoro-pyridazin-4-yl)-morpholine 2a (504 mg, 2.3 mmol) in THF (4 mL), and 
the mixture was stirred at rt for 16 h. The mixture was concentrated, partitioned between DCM (10 mL) 
and water (10 mL), the phases were separated and the aqueous phase further extracted with DCM (2 x 
10 mL). The organic phases were combined, dried and concentrated. Purification by column 
chromatography on silica gel using hexane:ethyl acetate 1-25% as gradient elution, followed by 
recrystallisation from ethanol gave 3-fluoro-4-morpholin-4-yl-9-oxa-10-thia-1,2-diaza-anthracene 9b 
(476 mg, 68%) as pale yellow crystals; mp 167.7 – 169.1 °C (Found: [MH]+ , 306.0707. C14H12FN3O2S 
requires [MH]+ , 306.0713); δH 3.24 (4H, td, 3JHH 4.7, 5JHF 2.1, CH2N), 3.85 (4H, t, 3JHH 4.7, CH2O), 
7.07 – 7.10 (2H, m, H-6, H-8), 7.13 – 7.15 (1H, m, H-7), 7.20 – 7.22 (1H, m, H-5); δC 49.9 (d, 4JCF 3.9, 
CH2N), 67.2 (d, 5JCF 1.3, CH2O), 114.5 (s, C-10a), 118.9 (s, C-8), 123.5 (d, 3JCF 8.0, C-4a), 125.7 (s, C-
6), 126.3 (s, C-7), 129.3 (s, C-5), 134.1 (d, 2JCF 26.3, C-4), 149.9 (d, 4JCF 1.0, C-9a), 159.3 (s, C-8a), 
160.3 (d, 1JCF 243.0, C-3); δF -90.0 (s); m/z (AP+) 305 ([M]+, 100%). 
 
4-Ethylsulfanyl-3-fluoro-5,8-dimethyl-5,6,7,8-tetrahydro-pyrazino[2,3-c]pyridazine 9c 
A mixture consisting of DIPEA (0.7 mL, 4 mmol), N,N'-dimethyl-ethane-1,2-diamine (0.16 mL, 1.6 
mmol), 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (200 mg, 1.0 mmol) and THF (4 mL) was stirred 
at rt for 16 h. The mixture was concentrated, partitioned between DCM (10 mL) and water (10 mL), the 
phases were separated and the aqueous phase further extracted with DCM (2 x 10 mL). The organic 
phases were combined, dried (MgSO4) and concentrated. Purification by column chromatography on 
silica gel using hexane:ethyl acetate (1:9) as eluent gave 4-ethylsulfanyl-3-fluoro-5,8-dimethyl-5,6,7,8-
tetrahydro-pyrazino[2,3-c]pyridazine 9c (191 mg, 77%) as a white solid; mp 78.1 – 80.0 °C (Found: C, 
49.4; H, 6.2; N, 23.0. C10H15FN4S requires: C, 49.6; H, 6.2; N, 23.1%); δH 1.19 (3H, t, 3JHH 7.4, 
CH3CH2S), 2.78 (2H, q, 3JHH 7.4, CH2S), 3.11 (3H, s, CH3), 3.31 (3H, s, CH3), 3.30 – 3.32 (2H, m, 
CH2N), 3.46 – 3.49 (2H, m, CH2N); δC 14.4 (s, CH3CH2S), 29.1 (d, 4JCF 4.4, CH2S), 37.8 (s, CH3N), 
43.1 (s, CH3N), 46.7 (s, CH2N), 51.8 (s, CH2N), 101.9 (d, 2JCF 36.1, C-4), 141.6 (d, 3JCF 5.2, C-4a), 
150.8 (s, C-8a), 162.3 (d, 1JCF 227.0, C-3); δF -87.0 (s); m/z (EI+) 242 ([M]+, 100%). 
 
4-Ethylsulfanyl-3-fluoro-9-oxa-10-thia-1,2-diaza-anthracene 9d 
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A mixture consisting of DIPEA (0.40 mL, 2.3 mmol), 2-mercaptophenol (0.08 mL, 0.8 mmol), 4-
ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (150 mg, 0.77 mmol) and THF (4 mL) was stirred at rt for 
16 h. The mixture was then concentrated, partitioned between DCM (10 mL) and water (10 mL), the 
phases were separated and the aqueous phase further extracted with DCM (2 x 10 mL). The organic 
phases were combined, dried and concentrated. Purification by column chromatography on silica gel 
using toluene:ethyl acetate (19:1) as eluent gave 4-ethylsulfanyl-3-fluoro-9-oxa-10-thia-1,2-diaza-
anthracene 9d (161 mg, 74%) as yellow crystals; mp 121.4 – 123.0 °C (Found: [MH]+, 281.0220. 
C12H9FN2OS2 requires [MH]+, 281.0219); δH 1.34 (3H, t, 3JHH 7.4, CH3), 3.14 (2H, qd, 3JHH 7.4, 5JHF 
1.0, CH2), 7.07 – 7.09 (2H, m, H-6, H-8), 7.12 – 7.14 (1H, m, H-7), 7.19 – 7.23 (1H, m, H-5); δC 15.3 
(s, CH3), 28.8 (d, 4JCF 6.9, CH2), 114.4 (s, C-10a), 118.8 (s, C-8), 124.0 (d, 2JCF 36.3, C-4), 125.8 (s, C-
6), 126.4 (s, C-7), 129.4 (s, C-5), 133.2 (d, 3JCF 4.9, C-4a), 149.4 (s, C-8a), 157.6 (d, 4JCF 1.9, C-9a), 
162.9 (d, 1JCF 238.2, C-3); δF -82.2 (s); m/z (AP+) 280 ([M]+, 100%). Crystal data for 9d: 
C12H9N2OFS2, M = 280.33, monoclinic, space group P21/n, a = 10.6924(5), b = 9.8670(4), c = 
11.0623(5) Å, β = 92.44(1)°, U = 1166.03(9) Å3, F(000) = 576, Z = 4, Dc = 1.597 mg m-3, µ = 0.457 
mm-1. 10747 reflections were collected yielding 3249 unique data (Rmerg = 0.0657). Final wR2(F2) = 
0.1129 for all data (199 refined parameters), conventional R1(F) = 0.0429 for 2369 reflections with 
I≥2σ(I), GOF = 1.008. CCDC-1486847. 
 
 
4-Ethylsulfanyl-3-fluoro-10H-9-oxa-1,2,10-triaza-anthracene 9e 
A mixture consisting of DIPEA (0.40 mL, 2.3 mmol), 2-aminophenol (84 mg, 0.77 mmol), 4-
ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (150 mg, 0.77 mmol) and THF (4 mL) was heated at 100 °C 
(microwave) for 5 min. The mixture was concentrated, partitioned between DCM (10 mL) and water 
(10 mL), the phases were separated and the aqueous phase further extracted with DCM (2 x10 mL). 
The organic phases were combined, dried (MgSO4) and concentrated. Purification by column 
chromatography on silica gel using hexane:ethyl acetate:DCM (5:2:3) as eluent gave 4-ethylsulfanyl-3-
fluoro-10H-9-oxa-1,2,10-triaza-anthracene 9e (153 mg, 75%) as a yellow solid; mp 260 °C (with 
decomposition) (Found: [MH]+, 264.0597. C12H10FN3OS requires [MH]+, 264.0607); δH 1.31 (3H, t, 
3JHH 7.4, CH3), 1.62 (1H, br. s, NH), 2.90 (2H, q, 3JHH 7.4, CH2), 6.63 – 6.65 (1H, m, H-5), 6.87 – 6.94 
(3H, m, ArH); δC 15.2 (s, CH3), 28.9 (d, 4JCF 3.1, CH2), 102.2 (d, 2JCF 40.1, C-4), 114.6 (s, C-5), 117.1 
(s, C-8), 124.7 (s, C-7), 125.0 (s, C-6), 125.8 (s, C-10a), 137.6 (d, 3JCF 7.1, C-4a), 142.8 (s, C-8a), 
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153.4 (d, 4JCF 0.9, C-9a), 164.4 (d, 1JCF 235.1, C-3); δF -81.0 (s); m/z (AP+) 263 ([M]+, 100%). Crystal 
data for 9e: C12H10N3SFO, M = 263.29, orthorhombic, space group P ca21, a = 12.566(9), b = 
5.2062(4), c = 35.081(3) Å, U = 2295.0(17) Å3, F(000) = 1088, Z = 8, Dc = 1.524 mg m-3, µ = 0.286 
mm
-1
. 13348 reflections were collected yielding 4103 unique data (Rmerg = 0.0642). Final wR2(F2) = 
0.1088 for all data (336 refined parameters), conventional R1(F) = 0.0490 for 2874 reflections with 
I≥2σ(I), GOF = 1.014. CCDC-1486849. 
 
 
4-Ethylsulfanyl-3-fluoro-10H-9-thia-1,2,10-triaza-anthracene 9f 
A mixture consisting of DIPEA (1.4 mL, 7.9 mmol), 2-aminophenol (0.28 mL, 1.9 mmol), 4-
ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (397 mg, 2.0 mmol) and THF (4 mL) was heated at 100 °C 
(microwave) for 30 min. The mixture was concentrated, partitioned between DCM (10 mL) and water 
(10 mL), the phases were separated and the aqueous phase further extracted with DCM (2 x 10 mL). 
The organic phases were combined, dried (MgSO4) and evaporated. Recrystallisation from chloroform 
gave 4-ethylsulfanyl-3-fluoro-10H-9-thia-1,2,10-triaza-anthracene 9f (333 mg, 63%) as yellow 
crystals; mp 249.2 – 251.8 °C (Found: [MH]+, 280.0378. C12H10FN3S2 requires [MH]+, 280.0378); δH 
1.35 (3H, t, 3JHH 7.4, CH3), 2.48 (1H, br. s, NH), 3.11 (2H, qd, 3JHH 7.4, 5JHF 0.8, CH2), 6.83 – 6.88 
(3H, m, ArH), 7.05 – 7.07 (1H, m, H-8); δC 15.3 (s, CH3), 28.8 (d, 4JCF 6.9, CH2), 113.8 (s, C-8a), 
117.0 (s, C-5), 122.7 (d, 2JCF 38.4, C-4), 124.3 (s, C-7), 126.1 (s, C-8), 129.2 (s, C-6), 135.4 (d, 3JCF 
4.6, C-4a), 135.8 (s, C-10a), 151.7 (s, C-9a), 160.8 (d, 1JCF 237.5, C-3); δF -85.6 (s); m/z (AP+) 279 
([M]+, 100%). 
 
4-Ethylsulfanyl-3-fluoro-1,2,4b,9-tetraaza-fluorene 9g 
A mixture consisting of DIPEA (0.70 mL, 4.0 mmol), pyridin-2-ylamine (143 mg, 1.5 mmol), 4-
ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (199 mg, 1.03 mmol) and THF (4 mL) was heated at 150 °C 
(microwave) for 30 min. The mixture was concentrated, partitioned between DCM (10 mL) and water 
(10 mL), the phases were separated and the aqueous phase further extracted with DCM (2 x 10 mL). 
The organic phases were combined, dried (MgSO4) and concentrated. Purification by column 
chromatography on silica gel using hexane:ethyl acetate (1:9) as eluent followed by recrystallisation 
from ethanol gave 4-ethylsulfanyl-3-fluoro-1,2,4b,9-tetraaza-fluorene 9g (35 mg, 14%) as orange 
crystals; mp 197.8 – 199.5 °C (Found: [MH]+, 249.0601. C11H9FN4S requires [MH]+, 249.0610); δH 
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1.38 (3H, t, 3JHH 7.4, CH3), 3.32 (2H, qd, 3JHH 7.4, 5JHF 0.7, CH2), 6.97 (1H, td, 3JHH 7.2, 3JHH 6.8, 4JHH 
1.1, H-6), 7.64 (1H, ddd, 3JHH 9.4, 3JHH 6.8, 4JHH 1.3, H-7), 7.79 (1H, dt, 3JHH 9.4, 5JHH 1.2, 4JHH 1.1, H-
8), 9.44 (1H, dt, 3JHH 7.2, 4JHH 1.3, 5JHH 1.2, H-5); δC 15.4 (s, CH3), 26.9 (d, 4JCF 7.5, CH2), 111.1 (d, 
2JCF 38.5, C-4), 112.0 (s, C-8), 119.1 (s, C-6), 126.4 (d, 3JCF 8.0, C-4a), 129.5 (s, C-7), 133.7 (s, C-5), 
153.3 (d, 4JCF 0.9, C-9a), 158.8 (s, C-8a), 160.7 (d, 1JCF 229.2, C-3); δF -89.4 (s); m/z (ES+) 249 
([MH]+, 100%). 
 
4-Ethylsulfanyl-3-fluoro-8-methyl-1,2,4b,9-tetraaza-fluorene 9h 
A mixture consisting of DIPEA (0.70 mL, 4.0 mmol), pyridin-2-ylamine (0.15 mL, 1.29 mmol), 4-
ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (200 mg, 1.03 mmol) and THF (4 mL) was stirred at rt for 7 
d. The mixture was concentrated, partitioned between DCM (10 mL) and water (10 mL), the phases 
were separated and the aqueous phase further extracted with DCM (2 x 10 mL). The organic phases 
were combined, dried (MgSO4) and concentrated. Purification by column chromatography on silica gel 
using hexane:ethyl acetate (1:9) as eluent gave 4-ethylsulfanyl-3-fluoro-8-methyl-1,2,4b,9-tetraaza-
fluorene 9h (134 mg, 50%) as orange crystals; mp 160.2 – 161.1 °C (Found: [MH]+, 263.0760. 
C12H11FN4S requires [MH]+, 263.0767); δH 1.37 (3H, t, 3JHH 7.3, CH3CH2S), 2.72 (3H, s, CH3), 3.30 
(2H, qd, 3JHH 7.3, 5JHF 0.9, CH2), 6.89 (1H, dd, 3JHH 7.0, 3JHH 6.9, H-6), 7.42 (1H, d, 3JHH 6.9, H-7), 
9.31 (1H, d, 3JHH 7.0, H-5); δC 15.3 (s, CH3CH2S), 17.6 (s, CH3), 29.5 (d, 4JCF 7.2, CH2), 110.8 (d, 2JCF 
39.4, C-4), 112.1 (s, C-7), 126.9 (s, C-5), 126.9 (d, 3JCF 7.9, C-4a), 129.3 (s, C-8), 131.5 (s, C-6), 154.1 
(d, 4JCF 1.0, C-9a), 158.7 (s, C-8a), 160.7 (d, 1JCF 228.9, C-3), δF -89.6 (s); m/z (EI+) 262 ([M]+, 100%). 
Crystal data for 9h: C12H11N4SF, M = 262.31, monoclinic, space group P21/c, a = 3.9174(1), b = 
16.8084(2), c = 17.1269(2) Å, β = 92.58(1)°, U = 1126.58(3) Å3, F(000) = 544, Z = 4, Dc = 1.547 mg 
m-3, µ = 0.286 mm-1. 15223 reflections were collected yielding 3149 unique data (Rmerg = 0.0487). 
Final wR2(F2) = 0.1154 for all data (207 refined parameters), conventional R1(F) = 0.0340 for 2828 
reflections with I≥2σ(I), GOF = 1.069. CCDC-1486845. 
 
 
4-Ethylsulfanyl-3-fluoro-6-methyl-furo[2,3-c]pyridazine-5-carboxylic acid ethyl ester 9i 
A mixture consisting of DIPEA (0.82 mL, 4.7 mmol), 3-oxo-butyric acid ethyl ester (0.17 mL, 1.3 
mmol), 4-ethylsulfanyl-3,5,6-trifluoro-pyridazine 2k (234 mg, 1.21 mmol) and THF (4 mL) was heated 
at 180 °C (microwave) for 90 min. The mixture was concentrated, partitioned between DCM (10 mL)  
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and water (10 mL), the phases were separated and the aqueous phase further extracted with DCM (2 x 
10 mL). The organic phases were combined, dried (MgSO4) and concentrated. Purification by column 
chromatography on silica gel using hexane:ethyl acetate (2:1) as eluent gave 4-ethylsulfanyl-3-fluoro-6-
methyl-furo[2,3-c]pyridazine-5-carboxylic acid ethyl ester 9i (95 mg, 28%) as a colourless oil; (Found: 
[MH]+, 285.0711. C12H13FN2O3S requires [MH]+, 285.0709); δH 1.29 (3H, t, 3JHH 7.4, SCH2CH3), 1.43 
(3H, t, 3JHH 7.2, OCH2CH3), 2.77 (3H, s, CH3), 3.18 (2H, qd, 3JHH 7.4, 5JHF 2.3, SCH2), 4.43 (2H, q, 
3JHH 7.2, OCH2); δC 14.3 (s, CH3), 14.9 (d, 5JCF 1.9, SCH2CH3), 15.0 (s, OCH2CH3), 28.6 (d, 4JCF 11.5, 
SCH2), 61.8 (s, OCH2), 111.0 (d, 3JCF 4.7, C-4a), 122.8 (d, 2JCF 34.8, C-4), 126.6 (d, 4JCF 6.6, C-7a), 
161.7 (s, C-5), 162.1 (s, C-6), 162.9 (d, 1JCF 232.4, C-3), 168.3 (s, C=O); δF -84.97 (s); m/z (ES+) 285 
([MH]+, 100%). 
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